[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National Cancer Centre, Singapore\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":685},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,27,0,25,[9,51,83,111,141,161,186,219,237,267,292,311,339,370,394,419,452,477,507,534,560,586,611,634,658],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100478949","phase-2-deep-multi-omics-phenotyping-to-predict-response-resistance-and-recurrence-to-adjuvant-atezolizumab-plus-bevacizumab-in-resected-hepatocellular-carcinoma-100478949",false,"NCT05516628","Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma","Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma (HCC)","EMPHASIS","Inclusion Criteria:\n\n1. Patient is willing, able and mentally competent to provide written informed consent prior to any testing undertaken for this study protocol, including screening tests and evaluations that are not considered to be part of the patient's routine care.\n2. Male and female patients, age 21 to 90 at the time of signature of the informed consent form.\n3. Patient is able to comply with scheduled visits, assessments and other study procedures.\n4. Patient diagnosed with HCC or its histological variants who has undergone a resection within 4-12 weeks prior to Day 1 of Cycle 1.\n\n * Multimodality treatment is not permitted, for example resection and ablation\n * Combination treatment is not permitted.\n5. Patient has clinically AND histologically proven HCC after liver resection as described below:\n\n * Patients must have documented histological HCC confirmation of negative surgical margins (R0) which is documented in a pathology report (patients with microscopically positive \\[R1\\] or grossly positive \\[R2\\] resection margins or unknown margins will be excluded from the study).\n * Patients must have disease-free status documented within 4 weeks prior to Day 1 of Cycle 1 by a complete physical examination and radiographic images, with no subsequent evidence of residual or recurrent disease prior to Day 1 of Cycle 1. A complete set of baseline (post-resection) radiographic images and accompanying report must be available prior to Day 1 of Cycle 1.\n6. Patient has an absence of major macrovascular (gross vascular) invasion of the portal vein (Vp3 or Vp4) or major macrovascular invasion in the inferior vena cava (Vv3).\n7. Patient has an absence of extrahepatic spread as confirmed by CT or MRI scan of the chest, abdomen, pelvis, and head prior to and following resection . If head scan was not performed prior to resection, this must be performed after resection.\n8. Patient has a full recovery from surgical resection within 4 weeks prior to Day 1 of Cycle 1.\n9. Patient is at high risk for HCC recurrence after resection as defined below:\n\n * Tumour confined to the liver that is (i) beyond the 'up-to-7' criteria, as defined as the sum of the diameter of the largest tumour (in cm) and the number of tumours, or (ii) with macrovascualr invasion (Vp1 or Vp2).\n * In the event that the pathology and the pre- resection radiology report are discordant with regards to tumour size and number, the modality demonstrating the largest tumour size and number should be used to determine high risk features. If macrovascular invasion of Vp1 or Vp2 is detected on either the pre-operative CT\u002FMRI scan or the pathology report, this should be a high-risk feature\n10. Patient is known to be negative for the Human Immunodeficiency Virus (HIV).\n11. Patient with documented virology status of hepatitis, as confirmed by screening HBV and HCV tests\n\n * For patients with active HBV: HBV DNA \\\u003C 500 IU\u002FmL during screening, initiation of anti-HBV treatment at least 14 days prior to Day 1 of Cycle 1 and willingness to continue anti-HBV treatment during the study (per local standard of care; e.g., entecavir). Patients with HBV DNA \\> 500 IU\u002FmL should be continued on antiviral treatment to obtain HBV DNA \\\u003C 500 IU\u002FmL before Day 1 of Cycle 1. Antiviral treatment shall continue throughout the entire Atezo+Bev treatment phase.\n * Patients with HCV, either with resolved infection (as evidenced by detectable antibody) or chronic infection (as evidenced by detectable HCV RNA), are eligible\n * For patients with detectable HCV RNA and for whom HCV treatment is deemed appropriate by the investigator, treatment should begin no sooner than 6 months following resection consistent with AASLD guidelines\n12. Patient is willing to receive an esophagogastroduodenoscopy, either before resection as part of pre-procedure work-up or following resection, and assessment and treatment of varices of all sizes per local standard of care prior to Day 1 of Cycle 1.\n13. Patient is willing to receive an electrocardiogram, either before resection as part of pre-procedure work-up or following resection, prior to Day 1 of Cycle 1.\n14. Patient with Child-Pugh A (up to 6 points) without clinical ascites before surgery\n15. Patient with ECOG performance status 0-1.\n16. Patient has adequate hematological, renal and hepatic function, defined by the following laboratory test results, obtained within 7 days prior to Day 1 of Cycle 1 unless otherwise specified:\n\n * AST, ALT, and ALP ≤ 5 × ULN\n * Serum bilirubin ≤ 3 × ULN\n * Albumin ≥ 28 g\u002FL (2.8 g\u002FdL)\n * Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 30 mL\u002Fmin (calculated using the Cockcroft-Gault formula)\n * Hemoglobin ≥ 90 g\u002FL (9 g\u002FdL) Patients may be transfused to meet this criterion.\n * Platelet count ≥ 75 × 10\\*\\*9\u002FL (75,000\u002FµL) without transfusion\n * Lymphocyte count ≥ 0.5 × 10\\*\\*9\u002FL (500\u002FµL)\n * ANC ≥ 1.5 × 10\\*\\*9\u002FL (1500\u002FµL) without granulocyte colony-stimulating factor support\n * For patients not receiving therapeutic anticoagulation: INR or aPTT ≤ 2 × ULN\n * Urine dipstick for proteinuria \\\u003C 2 + (within 7 days prior to Day 1 of Cycle 1) Patients discovered to have ≥ 2 + proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection (or an alternative method such as protein:creatinine ratio, per local guidance) and must demonstrate \\\u003C 1 g of protein in 24 hours.\n17. Patient is estimated to have a life expectancy of at least 3 months without any active treatment.\n18. Patient is deemed suitable for protocol treatment as determined by clinical assessment undertaken by the site Investigator.\n19. (For female patients) Patient is either postmenopausal or, if premenopausal, must have a negative pregnancy test and agree to use two forms of contraception if sexually active during the treatment period, for at least 5 months after the last dose of atezolizumab and 6 months after the last dose of bevacizumab.\n20. (For male patients) Patient is surgically sterile, or if sexually active and having a pre-menopausal female partner, must be using an acceptable form of contraception during the treatment period and for 6 months after the last dose of bevacizumab.\n\nExclusion Criteria:\n\n1. Patient is unable to provide informed consent or refuse blood taking.\n2. Patient has evidence of residual, recurrent, or metastatic disease prior to initiation of treatment.\n3. Patient has clinically significant ascites or any other clinical signs of liver failure on physical examination at time of enrolment.\n4. Patient has a history of hepatic encephalopathy.\n5. Patient has a bleeding event due to untreated or incompletely treated esophageal and\u002For gastric varices prior to Day 1 of Cycle 1.\n6. Patient has active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis, with the following exceptions:\n\n * Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study.\n * Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.\n * Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:\n\n * Rash must cover \\\u003C 10% of body surface area.\n * Disease is well controlled at baseline and requires only low-potency topical corticosteroids.\n * There is no occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the 12 months prior to Day 1 of Cycle 1.\n7. Patient has a history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on chest CT scan at screening.\n8. Patient has significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to Day 1 of Cycle 1, unstable arrhythmia, or unstable angina\n9. Patient has a history of malignancy other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year overall survival \\[OS\\] rate \\> 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer. Effectively treated malignancies,including HCC that have been in remission for over 5 years can be allowed as they are highly likely to have been cured.\n10. Patient has active tuberculosis at screening\n11. Patient has a severe infection within 4 weeks prior to Day 1 of Cycle 1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia, or any active infection that in the opinion of the investigator, could impact patient safety\n12. Patient has received treatment with therapeutic oral or IV antibiotics within 2 weeks prior to Day 1 of Cycle 1\n\n • Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study.\n13. Patient has prior allogeneic stem cell or solid organ transplantation\n14. Patient is on the waiting list for liver transplantation\n15. Patient has any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications\n16. Patient has a co-infection with HBV and HCV or Hepatitis D viral infection\n\n • Patients with a history of HCV infection but who are negative for HCV RNA by polymerase chain reaction will be considered to be negative for HCV infection.\n17. Patient has clinically significant uncontrolled or symptomatic hypercalcemia (ionized calcium \\> 1.5 mmol\u002FL, calcium \\> 12mg\u002FdL, or corrected serum calcium \\> ULN)\n18. Patient has a history of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins\n19. Patient has known hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab or bevacizumab formulations\n20. Patient has received any treatment for HCC prior to resection, including previous liver resection, systemic therapy (including investigational agents) and locoregional therapy (e.g. RFA, TACE, SIRT), radiotherapy, immunotherapy, chemotherapy or neo-adjuvant chemotherapy other than the planned surgery. However, patient who has received previous HCC resection more than 5 years ago is deemed to have a de-novo liver tumour and therefore can be included.\n\n * Prior use of herbal therapies or traditional Chinese medicines with anti-cancer activity included in the label is allowed, but such therapies must be discontinued at least 7 days prior to Day 1 of Cycle 1 and are prohibited during the study.\n * Portal vein embolization used to increase the functional liver remnant prior to surgery is permitted.\n21. Patient has received or plans to receive treatment with a live, attenuated vaccine within 4 weeks prior to Day 1 of Cycle 1, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab\n22. Patient has received prior treatment with investigational therapy within 4 weeks prior to Day 1 of Cycle 1\n23. Patient has prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies\n24. Patient has received prior treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin-2) within 4 weeks or 5 drug elimination half-lives (whichever is longer) prior to Day 1 of Cycle 1\n25. Patient has received prior treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumour necrosis factor-α \\[TNF-α\\] agents) within 2 weeks prior to Day 1 of Cycle 1, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions:\n\n * Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible.\n * Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.\n26. Patient has inadequately controlled arterial hypertension (defined as systolic blood pressure \\[BP\\] \\> 150 mmHg and\u002For diastolic BP \\> 100 mmHg), based on an average of at least three BP readings at two or more sessions\n\n • Anti-hypertensive therapy to achieve these parameters is allowed.\n27. Patient has a history of hypertensive crisis or hypertensive encephalopathy\n28. Patient has significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1 of Cycle 1\n29. Patient has a history of hemoptysis (≥ 2.5 mL of bright red blood per episode) within 1 month prior to Day 1 of Cycle 1\n30. Patient has evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)\n31. Current or recent (within 10 days prior to Day 1 of Cycle 1) use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purpose\n\n * Prophylactic anticoagulation for the patency of venous access devices is allowed provided the activity of the agent results in an INR \\\u003C 1.5 × ULN and aPTT is within normal limits (according to institutional standards) within 14 days prior to Day 1 of Cycle 1.\n * Prophylactic use of low-molecular-weight heparin (LWMH; i.e., enoxaparin 40 mg\u002Fday) is allowed. However, the use of direct oral anticoagulant therapies such as dabigatran (Pradaxa®) and rivaroxaban (Xarelto®) is not recommended due to bleeding risk. Benefits and risks should be assessed and caution exercised for use of direct oral anticoagulants. The investigator should consider switching to other approved anticoagulants due to the risk of upper GI bleeding in patients with HCC.\n32. Patient has received a core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 3 days prior to Day 1 of Cycle 1\n33. Patient has a history of GI fistula, GI perforation, or intra-abdominal abscess within 6 months prior to Day 1 of Cycle 1\n34. Patient has evidence of abdominal free air that is not explained by paracentesis or recent surgical procedure\n35. Patient has a serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture\n36. Patient is receiving or plans to receive a major surgical procedure within 4 weeks prior to Day 1 of Cycle 1 or anticipation of need for a major surgical procedure during the study\n37. Patient has a history of clinically significant intra-abdominal inflammatory process within 6 months prior to Day 1 of Cycle 1, including, but not limited to, peptic ulcer disease, diverticulitis, or colitis\n38. (For female patients) Patient is pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the final dose of atezolizumab or within 6 months after the final dose of bevacizumab\n\n * Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to Day 1 of Cycle 1.","ALL","21 Years","90 Years",{"count":22,"type":23},30,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","Hepatocellular carcinoma (HCC) is the 7th most common cancer worldwide but is the 4th deadliest, because diagnosis tend to be late and current systemic therapies are poorly efficacious. Within the same tumour, different parts of the HCC can belong to separate molecular sub-groups. In addition, there is currently no validated predictive biomarkers to help clinicians select the best therapy for an individual patient. This challenge poses an urgent, unmet clinical need.\n\nTo address this, the multi-disciplinary research program Precision Medicine in Liver Cancer across an Asia-Pacific Network (PLANet 1.0) was conceptualized and successfully conducted from 2016-22. The program uncovered novel insights into the highly heterogeneous molecular landscape of HCC and novel mechanisms, including how HCC reverts to fetal forms to escape the body's immunological defence.\n\nThese investigations will be continued in PLANet 2.0 and in this new phase, the research team will investigate patients receiving best-in-class therapeutics in 2 investigator-initiated clinical studies (AHCC12 and AHCC13), including Atezolizumab plus Bevacizumab (Atezo+Bev) and Yttrium-90, which allows the research team to collect longitudinal, before and after treatment biosamples and clinical data. These clinical studies will serve as proof-of-concept to the study team's translational findings and allow it to uncover predictive biomarkers which will help clinicians to institute more efficacious and personalized treatment in the future. The research team comprises of experts in different complementary fields (epigenomics, genomics, immunomics, metabolomics, proteomics, clinical science and data science) and across different institutions. This allows the team to adopt an integrative approach in understanding the landscape of the HCC tumour micro-environment and biomarkers co-localisation, and their role in tumour evolution and therapeutic response. By adopting a wide spectrum of converging investigations, PLANet 2.0 will identify and validate biomarkers that correlate with clinical outcomes (response, resistance and recurrence).",[29],"Hepatocellular Carcinoma",[31,32,33,34,35,36,37],"Hepatocellular Carcinoma (HCC)","Adjuvant Atezolizumab","Adjuvant Bevacizumab","Biomarkers","Multiomics profiles","Spatial TME profiles","Surgically resected HCC","RECRUITING","2026-06-24",{"date":41,"type":42},"2026-06-29","ACTUAL",{"date":44,"type":42},"2023-02-28",{"date":46,"type":23},"2027-03",{"name":48,"class":49},"National Cancer Centre, Singapore","OTHER",6,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":24,"phases":61,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},"100510703","phase-2-metronomic-capecitabine-oxaliplatin-and-ugt1a1-genotype-directed-irinotecan-in-metastatic-pancreatic-cancer-patients-100510703","NCT05929885","Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients","A Phase II Study of Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients.","Inclusion Criteria:\n\nThe patient must meet all of the inclusion criteria to participate in the study.\n\n1. Aged above 21\n2. Histopathological diagnosis of pancreatic cancer\n3. Advanced disease not amenable to curative resection (locally advanced or metastatic disease)\n4. Measureable disease by RECIST 1.1 criteria\n5. Life expectancy of at least 12 weeks\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n7. Adequate hematologic function (granulocyte count ≥ 1.5 × 10\\*\\*9\u002FL, platelet count ≥ 100 × 10\\*\\*9\u002FL),\n8. Adequate hepatic function (total bilirubin ≤ 1.5 x the upper limits of normal \\[ULN\\], AST and ALT, ALP ≤ 3 x ULN or \\\u003C 5 x ULN in case of hepatic involvement),\n9. Adequate renal function (creatinine clearance \\> 50 mL\u002Fmin) will be eligible for inclusion into the study.\n10. Able to provide written and informed consent\n\nExclusion Criteria:\n\nAny patient meeting any of the exclusion criteria at baseline will be excluded from participation.\n\n1. History of another malignancy within 5 years prior to registration. Patients with a past history of adequately treated carcinoma-in-situ, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and superficial transitional cell carcinoma of the bladder are eligible. Patients with a history of other malignancies are eligible if they have been continuously disease free after definitive primary treatment for at least 5 years.\n2. Untreated CNS metastases or leptomeningeal disease. Patients with brain metastases that have been treated, and are asymptomatic, and have been stable for 3 or more months after treatment are allowed. A baseline CT or MRI brain is only required if there is clinical suspicion of CNS involvement.\n3. Concurrent illness, including severe infection, that may jeopardise the ability of the patient to undergo the procedures outlined in this protocol with reasonable safety\n4. Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol\n5. Treatment with palliative chemotherapy or radiotherapy within 4 weeks prior to enrolment into the study\n6. Major surgery within two weeks prior to enrolment into the study\n7. Patients on chronic immunosuppressive therapy\n8. Pregnancy, lactation or inadequate contraception. Women of childbearing potential must have a negative pregnancy test within 3 days of enrolment and agree to use a reliable means of contraception. Men must have been surgically sterilised or agree to use a barrier method of contraception\n9. Patients on anticoagulant therapy with vitamin K antagonists.","99 Years",{"count":60,"type":23},50,[26],"This is a single-centre, non-randomized, open label phase II trial to be conducted at the National Cancer Centre, Singapore (NCCS). Patients diagnosed with metastatic PDAC will be eligible to enrol.\n\nThe investigators hypothesize the anticancer activity of low dose OXIRI (LD-OXIRI) regimen comprising of metronomic oxaliplatin (O) and metronomic capecitabine (xeloda; X) in combination with UGT1A1-directed dosing of irinotecan (IRI) to be a tolerable regimen in patients with advanced PDAC and will lead to a favourable response rate.\n\nPatients will be prospectively enrolled in two stages - In stage 1, patients will be recruited and evaluated for response and toxicity. In stage 2, more patients will be recruited for further evaluation of response and toxicity.",[64],"Metastatic Pancreatic Cancer",[66,67,68,69,70,71,72,73],"Low Dose OXIRI (LDOXIRI)","Pancreatic Cancer","Irinotecan","Oxaliplatin","Capecitabine","Pharmacokinetics","Metronomic Chemotherapy","UGT1A1","2026-06-18",{"date":76,"type":42},"2026-06-23",{"date":78,"type":42},"2023-08-30",{"date":80,"type":23},"2027-02-28",{"name":48,"class":49},1,{"id":84,"slug":85,"hasResults":12,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":12,"sex":90,"minAge":19,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":24,"phases":93,"briefSummary":95,"conditions":96,"keywords":99,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},"100601873","exercise-therapy-and-cognitive-behavioural-therapy-for-fatigue-in-female-cancer-patients-in-singapore-100601873","NCT07116161","Exercise Therapy and Cognitive Behavioural Therapy for Fatigue in Female Cancer Patients in Singapore","Pilot Study of Exercise Therapy and Cognitive Behavioural Therapy for Fatigue in Female Cancer Patients in Singapore","Inclusion Criteria:\n\nPrimary cohort (N=90):\n\n1. Female\n2. ≥21 years of age\n3. Stage I-III breast cancer regardless of hormone receptor status or human epidermal growth factor receptor 2 (HER2) status\n4. Completed surgery\n5. Completed adjuvant chemotherapy, if indicated\n6. Reported fatigue (One-item fatigue scale score ≥ 4)\n7. Ability to read and communicate in English\n8. Willing to provide informed consent for the study participation\n\nExploratory cohort (N=10):\n\n1. Female\n2. ≥21 years of age\n3. Stage IV breast cancer regardless of hormone receptor status or human epidermal growth factor receptor 2 (HER2) status\n4. Completed surgery\n5. Currently receiving systemic therapy (e.g. endocrine therapy, chemotherapy, targeted therapy or immunotherapy)\n6. Reported fatigue (One-item fatigue scale score ≥ 4)\n7. Ability to read and communicate in English\n8. Willing to provide informed consent for the study participation\n\nExclusion Criteria for both cohorts:\n\n1. Pregnant or lactating\n2. Presence of dementia or major psychiatric disease\n3. Deemed medically unsuitable by medical team for low to moderate intensity exercise\n4. Unable or unwilling for tele-counselling sessions\n5. Uncontrolled pain or undiagnosed pain\n6. Low blood counts: Hb \\\u003C8.0, Platelet \\\u003C50K, ANC \\\u003C1\n7. Electrolyte imbalances: K \\\u003C3.0, Na \\\u003C130\n8. Cardiovascular diseases, including but not limited to: LVEF \\\u003C35%, uncontrolled arrhythmias, severe coronary artery disease, severe valvular heart disease, uncontrolled hypertension etc. not cleared by a cardiologist\n9. Active infection\n10. Currently engaged in moderate to vigorous physical activity","FEMALE",{"count":92,"type":23},100,[94],"NA","The purpose of this research study is to investigate the acceptability, feasibility, and effectiveness of exercise therapy and cognitive behavioral therapy (CBT) in improving fatigue levels and breast cancer treatment adherence in breast cancer patients.",[97,98],"Fatigue","Breast Cancer Female",[100,101],"Exercise Therapy","Cognitive Behavioural Therapy","2026-05-27",{"date":104,"type":42},"2026-05-29",{"date":106,"type":42},"2025-07-14",{"date":108,"type":23},"2027-12-31",{"name":48,"class":49},4,{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":12,"sex":18,"minAge":119,"maxAge":20,"enrollmentInfo":120,"targetDuration":4,"studyType":24,"phases":122,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":140},"100601487","restoring-bile-acid-homeostasis-via-lifestyle-adjustments-to-prevent-the-development-of-liver-cancer-100601487","NCT07111130","Restoring Bile Acid Homeostasis Via Lifestyle Adjustments to Prevent the Development of Liver Cancer","Prospective Interventional Study Evaluating the Modulation of Bile Acid Profiles, Gut Microbiome and Liver Health Through Lifestyle Adjustments in Individuals at High Risk of Developing Liver Cancer.","RE-BALANCE","Inclusion Criteria:\n\nThe following criteria are to be checked at the time of enrolment. The patient may only be included in the study if ALL of the following statements are FULFILLED:\n\n1. The patient is an existing participant of the ELEGANCE study and shows no evidence of hepatocellular carcinoma (HCC) at the time of enrolment into RE-BALANCE.\n2. Male and female patients aged 50 to 90 years at the time of informed consent are eligible. However, patients with cirrhosis may be included if they are aged 40 to 90 years.\n3. Negative for hepatitis B surface antigen (HBsAg) and hepatitis C antibody\n4. High-risk bile acid profile, defined as a 12-non-hydroxy\u002F12-hydroxy bile acid ratio below the threshold determined from ELEGANCE cohort data.\n5. Patient is able to comply with scheduled visits, assessments and other study procedures.\n6. Patient is willing to provide informed consent before enrolment in the study.\n\nExclusion Criteria:\n\nThe following criteria should be checked at the time of enrolment. If ANY applies, the patient must not be included in the study:\n\n1. Patient with confirmed diagnosis of HCC by the American Association for the Study of the Liver Disease (AASLD) imaging criteria or histology \u002F cytology within the last 5 years.\n2. Patient with Child Pugh C or decompensated cirrhosis at time of enrolment (based on the judgement of the Investigator).\n3. Patient with active hepatic encephalopathy at time of enrolment.\n4. Patient is known to be positive for the Human Immunodeficiency Virus (HIV).\n5. Patient has chronic liver diseases apart from steatosis or compensated cirrhosis (e.g., autoimmune hepatitis, primary biliary cholangitis. etc.).\n6. Uncontrolled diabetes mellitus requiring special dietary management or persistent unacceptable HbA1c levels.\n7. Use of weight-loss medications (e.g., GLP-1 agonists, Orlistat) within three months prior to enrolment or planned use during the study period.\n8. History of bariatric surgery or planned bariatric surgery during the study period.\n9. Patient has significant comorbidities expected to limit life expectancy to less than one year, or that would render diet or exercise unsafe\n\n 1. Diseases involving muscles, bones or joints that may impact the subjects' performance during exercise testing and exercise rehabilitation\n 2. Co-morbidities that may adversely affect exercise performance\n 3. Requiring an assistive aid with walking\n 4. Conditions that require strict dietary restrictions or impair ability to follow dietary interventions\n10. Patient has significant gastrointestinal diseases affecting nutrient absorption or requiring a special diet incompatible with study diet.\n11. Pregnancy or breastfeeding\n12. Current use of medications or supplements that significantly alter bile acid gastrointestinal absorption (e.g., bile acid sequestrants) that cannot be safely discontinued.\n13. Patient has severe food allergies or intolerances incompatible with the provided study diet.\n14. Patient has psychiatric or addictive disorders that may compromise his\u002Fher ability to give informed consent, or to comply with the study procedures.\n15. Patient is unable to provide informed consent or refuse blood taking and other investigations including LMS scans.\n16. Patient has any other condition which, in the opinion of the Investigators, would make the patient unsuitable for enrolment or could interfere with completion of the study.","40 Years",{"count":121,"type":23},90,[94],"This is a prospective, single-arm, non-randomized interventional study nested within the existing ELEGANCE cohort. Patients eligible for the RE-BALANCE study will be selected from the ELEGANCE cohort based on predefined high-risk criteria, specifically a low 12-non-hydroxy\u002F12-hydroxy bile acid ratio indicative of elevated hepatocarcinogenic risk.\n\nThe study comprises Baseline Assessments (Visit 1), Intervention Visits (Visit 2-8), and Follow-up Assessments (Visit 9-11).",[125],"Liver Diseases",[31,127,128,129,130],"Non-viral HCC","Interventional Study","Lifestyle Adjustments","Bile Acid, Microbiome and Liver Health Modulation","NOT_YET_RECRUITING","2026-05-12",{"date":134,"type":42},"2026-05-15",{"date":136,"type":23},"2026-07",{"date":138,"type":23},"2028-03",{"name":48,"class":49},14,{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":12,"sex":90,"minAge":19,"maxAge":58,"enrollmentInfo":147,"targetDuration":4,"studyType":24,"phases":149,"briefSummary":150,"conditions":151,"keywords":153,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":82},"100574959","evaluating-the-effectiveness-of-aromatherapy-for-alleviating-distress-in-breast-cancer-patients-before-radiotherapy-100574959","NCT06766058","Evaluating the Effectiveness of Aromatherapy for Alleviating Distress in Breast Cancer Patients Before Radiotherapy.","Inclusion Criteria:\n\n1. Aged 21 years old and above\n2. Confirmed diagnosis of breast cancer of any stage\n3. Scheduled to undergo radiotherapy for the first time\n4. Capable of providing informed consent\n\nExclusion Criteria:\n\n1. Physically or mentally incapable of providing verbal\u002Fwritten consent\n2. Known or suspected hypersensitivity\u002Fallergy to essential oils or any components of the formulations\n3. Airway hypersensitivity to fragrances, paint fumes or turpentine\n4. Taking medications for anxiety (e.g. benzodiazepines) before radiotherapy\n5. Pregnant, breastfeeding, or intending to conceive during study period",{"count":148,"type":23},300,[94],"ASTER is a multi-part study that aims to prospectively establish evidence for the implementation of aromatherapy as complementary therapy within cancer care in the Singapore context. ASTER 2 study evaluates how extracts from Asian aromatic plants with familiar aromas introduced as inhalation therapy can alleviate distress in breast cancer patients scheduled to undergo radiotherapy (RT).",[152],"Breast Cancer",[154],"Inhalation Aromatherapy",{"date":134,"type":42},{"date":157,"type":42},"2024-10-22",{"date":159,"type":23},"2027-06-01",{"name":48,"class":49},{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":167,"sex":18,"minAge":168,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":24,"phases":172,"briefSummary":173,"conditions":174,"keywords":176,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":180,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":50},"100494906","singapore-lung-cancer-screening-through-integrating-ct-with-other-biomarkers-solstice-100494906","NCT05724264","SingapOre Lung Cancer Screening Through Integrating CT With Other biomarkErs (SOLSTICE)","Inclusion Criteria:\n\nSmoker:\n\n* Participant is willing and able to give informed consent for participation in the study\n* Male or female, aged 50-80 years of age\n* No prior history of cancer, or cancer free in the last 5 years and not currently on cancer treatment\n* ECOG 0\u002F1\n* Current or former smokers with at least 30 pack years of smoking history\n* Willing to comply with study follow-up schedule and tests\n* Willing to cover the costs of downstream standard of care management and investigations including doctor's fee, CT scan and biopsy etc.\n* A Singapore citizen\u002FPermanent Resident of Singapore\n\nNon-Smoker:\n\n* Participant is willing and able to give informed consent for participation in the study\n* Male, or female, aged 50-80 years of age\n* No prior history of cancer, or cancer free in the last 5 years and not currently on cancer treatment\n* ECOG 0\u002F1\n* Never smoker, or has smoked less than 10 pack-years and has quit smoking for at least 15 years\n* Family history of lung cancer up to 2nd degree relatives\n* Willing to comply with study follow-up schedule and tests\n* Willing to cover the costs of downstream standard of care management and investigations including doctor's fee, CT scan and biopsy etc.\n* A Singapore citizen\u002FPermanent Resident of Singapore\n\nExclusion Criteria:\n\n* Uncontrolled medical comorbidity on enrolment\n* Previous diagnosis of cancer\n* Bleeding diathesis that will preclude blood sampling\n* Fear of blood draw or needles\n* Pregnancy",true,"50 Years","80 Years",{"count":171,"type":23},1000,[94],"This is a single arm screening study. All eligible participants will be subjected to low dose CT (LDCT) screening and biomarker testing.\n\nThe primary aim of the study is to determine the feasibility of conducting LDCT screening in at-risk populations for lung cancer in Singapore:\n\n* For the smoker population, LDCT screening for lung cancer will be implemented in accordance to Academy of Medicine, Singapore screening test guidelines with the aim of investigating the feasibility of instituting lung cancer screening clinical service in Singapore.\n* For the non-smoker population, LDCT screening for lung cancer will be introduced to systematically collect baseline data to better understand and provide evidence for lung adenocarcinoma in never-smoker phenotype that is unique to East Asia\u002FSingapore. This will help address unmet needs in local population research as reported by Academy of Medicine, Singapore, to validate risk factors and inform future screening guidelines for the at-risk population.\n\nScreening results will be reported based on Lung CT Screening Reporting \\& Data System (Lung-RADS).",[175],"Lung Cancer",[177,178,179],"Low Dose CT (LDCT) Screening","Lung CT Screening Reporting & Data System (Lung-RADS)","Lung cancer screening in smokers and non-smokers",{"date":134,"type":42},{"date":182,"type":42},"2022-07-21",{"date":184,"type":23},"2029-12-31",{"name":48,"class":49},{"id":187,"slug":188,"hasResults":12,"nctId":189,"briefTitle":190,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":58,"enrollmentInfo":193,"targetDuration":4,"studyType":194,"phases":4,"briefSummary":195,"conditions":196,"keywords":198,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":82},"100589579","innovating-access-to-novel-therapies-through-standardized-prospective-integration-of-response-evaluations-impact-inspire-100589579","NCT06956248","Innovating Access to Novel Therapies Through Standardized Prospective Integration of Response Evaluations (IMPACT-INSPIRE)","IMPACT-INSPIRE","Inclusion Criteria:\n\n1. Is equal to or greater than 21 years of age;\n2. Histologic or cytologic confirmed advanced solid tumours;\n3. Patients who have received and failed all standard anticancer therapy (if available) or are unsuitable for further standard anticancer therapy. Cancers with a poor prognosis or low expected response rate to standard treatment (as judged by the investigator on the basis of available evidence) may be screened with respect to an earlier line of treatment;\n4. Ability to understand and the willingness to provide written informed consent.\n\nExclusion Criteria:\n\n1. Specific contraindications to exposure to the off-label or non-standard therapy (as defined by the product label);\n2. Other comorbid conditions that may compromise assessing key outcomes or, in the judgement of the clinician, limit the ability of the patient to comply with the protocol.",{"count":60,"type":23},"OBSERVATIONAL","This observational study aims to assess the outcomes in patients with advanced treatment refractory cancers with matched molecular\u002Fprecision therapy as per their molecular profiling results after discussion at molecular tumour board.\n\n1. To standardize response assessment and data collection for patients that are receiving off-label or non-standard therapies based on MTB recommendations.\n\n \\- Establish a standardized response assessment process and data collection patients that are receiving off-label or non-standard therapies based on MTB recommendations.\n2. To demonstrate that it is feasible to standardize investigations and endpoints in this proof-of-concept study.\n\n * Through standard safety laboratory investigations (FBC, U\u002FE\u002FCr, LFT)\n * Through standard radiological imaging at 6-12 weeks with the key endpoint being best response during that imaging window, and disease control rate at 6 months.\n\nHypothesis: Our proposed IMPACT-INSPIRE study hypothesis is that standardised response assessment and data collection in patients with no available therapies receiving off-label systemic therapies, can provide a novel mechanism to assess oncological outcomes in this unique cohort of patients, generate hypothesis, and provide insights to future biomarker-driven drug development",[197],"Solid Tumor",[199,200,201,202,203,204,205,206,207,208,209,210],"Advanced Cancers","Solid Tumours","Off-label Cancer Therapies","Non-standard Cancer Therapies","Molecular Tumour Board (MTB)","Response Assessment","Real-World Data Collection","Precision Oncology","Translational Research","Patient Reported Outcomes (PROs)","Quality of Life (QOL)","Treatment Outcomes","2026-05-11",{"date":213,"type":42},"2026-05-13",{"date":215,"type":42},"2024-09-12",{"date":217,"type":23},"2035-03-12",{"name":48,"class":49},{"id":220,"slug":221,"hasResults":12,"nctId":222,"briefTitle":223,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":12,"sex":18,"minAge":226,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":194,"phases":4,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":236,"locationsCount":82},"100270928","individualized-molecular-profiling-for-allocation-to-clinical-trials-impact-project-100270928","NCT02806388","Individualized Molecular Profiling for Allocation to Clinical Trials (IMPACT) Project","IMPACT","Inclusion Criteria:\n\n* Confirmed histological diagnosis of solid tumor\n* Suitable for systematic treatment and clinical trials\n* ECOG (Eastern cooperative oncology group) performance status \\\u003C 2\n* Able to provide tumor tissue for molecular profiling\n* Able to understand and sign the informed consent form\n\nExclusion Criteria:\n\n* None","12 Years",{"count":228,"type":23},5500,"This study aims to screen tumor molecular profile for better selection of anticancer treatment, in particular, allocation to clinical trials if available.",[197],"2026-05-08",{"date":213,"type":42},{"date":234,"type":4},"2011-10",{"date":108,"type":23},{"name":48,"class":49},{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":245,"enrollmentInfo":246,"targetDuration":4,"studyType":24,"phases":248,"briefSummary":250,"conditions":251,"keywords":253,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":82},"100640125","phase-3-electroacupuncture-for-cognitive-toxicity-in-cancer-survivors-assessing-implementation-cost-and-effectiveness-for-integration-100640125","NCT07583979","Electroacupuncture for Cognitive Toxicity in Cancer Survivors: Assessing Implementation, Cost, and Effectiveness for Integration","ElectroAcupuncture to Manage Symptoms of Cognitive Toxicity in Cancer Survivors: Assessing impLementation, Cost, and effectIveness for inteGratioN (EAST-ALIGN)","EAST-ALIGN","Inclusion Criteria:\n\nSurvivor participants\n\n* Aged 21-85 years\n* Documented cancer diagnosis in electronic health records\n* Perceived by the survivor or oncology care provider that cognitive function has worsened since cancer diagnosis and\u002For beginning of cancer treatment\n* Able to understand English or Mandarin\n* Able to provide informed consent\n\nStakeholder participants\n\n* Aged ≥21 years\n* Identified as having a relevant role, experience, or perspective relating to the delivery, referral, coordination, or implementation of EA or supportive cancer care in the study context\n* Able to provide informed consent\n\nExclusion Criteria:\n\nSurvivor participants\n\n* Presence of brain metastases\n* Severe needle phobia\n* Known bleeding disorder (e.g. hemophilia, von Willebrand disease, thrombocytopenia).\n* Current use of antiplatelet or anticoagulant therapy (e.g. aspirin, clopidogrel, warfarin, enoxaparin, rivaroxaban, dabigatran)\n* Known blood-borne communicable disease (e.g. hepatitis B, hepatitis C, human immunodeficiency virus)\n* Presence of a pacemaker or other electronic implant, or a history of epilepsy\n* Current acupuncture treatment or acupuncture received within the past 3 months\n* Current pregnancy, planned pregnancy over the next 5 months, or breastfeeding.\n* Incapable of providing informed consent\n* Unable to complete study procedures\n\nStakeholder participants\n\n* Incapable of providing informed consent\n* Unable to complete study procedures","85 Years",{"count":247,"type":23},168,[249],"PHASE3","The goal of this clinical trial is to evaluate the clinical effectiveness and understand the biological mechanisms of electroacupuncture (EA) in reducing cognitive toxicity among cancer survivors. The study aims are:\n\n* To evaluate the clinical effectiveness of a 10-week EA regimen targeting neuropsychiatric-related acupoints in reducing cognitive toxicity among cancer survivors in Singapore.\n* To explore the biological mechanisms underlying EA's effects on cognitive function.\n* To assess the early implementation of EA for managing cognitive toxicity in cancer survivors.\n\nResearchers will compare results from the true EA arm, sham EA arm and waitlist control arm, to see if electroacupuncture can help improve cognitive issues related to cancer and its treatment, how it may work, and what factors may affect how it is delivered in cancer care.\n\nParticipants will:\n\n* Be assigned to either of the 3 arms (true EA, sham EA, waitlist control)\n* Received 10 EA sessions (if assigned to true or sham EA arm)\n* Complete 3 study assessment visits at baseline, Week 13, and Week 17\n* Be invited to a one-time interview to share their study experience (optional, if selected)",[252],"Cancer-related Cognitive Impairment",[254,255,256,252,257,258,259],"Electroacupuncture","Acupuncture","Traditional Chinese Medicine","Cognitive Toxicity","Oncology","Survivor","2026-05-06",{"date":213,"type":42},{"date":263,"type":23},"2026-07-01",{"date":265,"type":23},"2029-01-13",{"name":48,"class":49},{"id":268,"slug":269,"hasResults":12,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":167,"sex":18,"minAge":19,"maxAge":275,"enrollmentInfo":276,"targetDuration":4,"studyType":24,"phases":278,"briefSummary":279,"conditions":280,"keywords":282,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":82},"100519507","evaluation-and-implementation-preparation-of-a-proactive-palliative-care-model-enable-sg-100519507","NCT06044441","Evaluation and Implementation Preparation of a Proactive Palliative Care Model (ENABLE-SG)","ENABLE-SG (Educate, Nurture, Advise, Before Life Ends for Singapore) as a Proactive Palliative Care Model: Evaluation and Implementation Preparation","ENABLE-SG","Inclusion Criteria:\n\n* Inclusion criteria for patients:\n\n 1. Adult aged 21 and above\n 2. Within 60 days of being informed of an advanced cancer diagnosis, defined as metastatic or recurrent\u002F progressive Stage III\u002FIV solid tumour\n 3. Able to speak English or Chinese\n 4. Able to provide informed consent\n 5. Patients will NOT need to have a caregiver willing to participate in the ENABLE-SG programme.\n* Inclusion criteria for caregivers:\n\n 1. Adult aged 21 and above\n 2. Self-endorsing or identified by the enrolled patient as an unpaid spouse\u002Fpartner, relative or friend who knows them well and who provides regular support (at least 7 hours a week) due to their cancer and who does not have to live in the same dwelling\n 3. Caring for a patient with advanced cancer (see definition under patient inclusion criteria above)\n 4. Able to speak English or Chinese.\n 5. Able to provide informed consent\n* Inclusion criteria for healthcare professions:\n\n 1. 21 years or older.\n 2. Approached to participate in the ENABLE-SG study\n 3. Able to provide informed consent\n\nExclusion Criteria:\n\n* Exclusion criteria for patients:\n\n 1. Medical record documentation of an active severe mental illness, dementia, active suicidal ideation, uncorrected hearing loss\n 2. Unable to complete patient-reported outcome measures\n 3. Has been reviewed by palliative care services in the current model of palliative care.\n* Exclusion criteria for caregivers:\n\n 1. Self-reported severe mental illness, dementia, active suicidal ideation, uncorrected hearing loss\n 2. Unable to complete caregiver-reported outcomes.\n* Exclusion criteria for healthcare professional:\n\n 1. Healthcare professionals that are not providing care for cancer patients.\n 2. Unable to complete interviews.","120 Years",{"count":277,"type":23},715,[94],"The current interdisciplinary specialist palliative care model focuses on supporting patients with advanced cancer who have complex problems in the last weeks of life. Consequently, palliative care is often provided late and in response to uncontrolled symptoms during crises. Palliative care models should shift from this reactionary illness-stress paradigm to a proactive health-wellness approach that is integrated early in the patient's disease trajectory.\n\nA proactive early palliative care telehealth model, ENABLE (Educate, Nurture, Advise, Before Life Ends), was developed in the U.S. to coach patients with advanced cancers and their family caregivers on how to cope effectively with serious illness. By empowering individuals early before acute distress and symptoms occur, patients and families can better mitigate and avoid crises. Building on positive health outcomes demonstrated by the ENABLE model in the U.S., the study team has successfully pilot-tested a culturally adapted ENABLE-SG model in Singapore. This study seeks to test the effectiveness of this ENABLE-SG model among patients with recently diagnosed advanced cancer and their caregivers while simultaneously collecting data on real-world implementation.",[281],"Neoplasms",[283],"Palliative Care","2026-04-26",{"date":286,"type":42},"2026-04-30",{"date":288,"type":42},"2023-12-26",{"date":290,"type":23},"2027-08-31",{"name":48,"class":49},{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":194,"phases":4,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":82},"100419206","telegenetics-or-in-person-genetic-counselling-100419206","NCT04738708","Telegenetics or In-Person Genetic Counselling","Telegenetics or In-Person Genetic Counselling: A Comparison of Clinical Outcomes and Cost","Inclusion Criteria:\n\n* Age ≥ 21 years old.\n* Patients referred to CGS at NCCS for HBOC or Lynch syndrome pre-test genetic counselling.\n* Able to read and understand the English Language.\n* Able to consent and agree to be randomized to either telegenetics or in-person genetic counselling.\n\nExclusion Criteria:\n\n* Under the age of 21 years old.\n* Patients who require genetic results urgently.\n* Cognitive difficulty\u002F impairment or current psychiatric or physical illness (visual\u002F hearing\u002F neurological) which impairs sound judgement and accurate reporting of medical history over video consultation.",{"count":300,"type":23},150,"This study aims to compare clinical outcomes (informed choice and genetic counselling outcomes) and cost (provider and patient time, travel, and telehealth platform) between telegenetics and in-person genetic counselling.",[303],"Genetic Counselling",{"date":305,"type":42},"2026-04-28",{"date":307,"type":42},"2021-02-01",{"date":309,"type":23},"2026-10-06",{"name":48,"class":49},{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":4,"eligibilityCriteria":317,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":58,"enrollmentInfo":318,"targetDuration":4,"studyType":24,"phases":320,"briefSummary":321,"conditions":322,"keywords":324,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":338},"100523241","phase-2-tislelizumab-and-metronomic-capecitabine-as-maintenance-in-high-risk-locoregionally-advanced-nasopharyngeal-carcinoma-100523241","NCT06093061","Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma","RIBBON-LA-01: Single-arm, Open-label, Phase 2 Trial of Tislelizumab and Metronomic Capecitabine as Maintenance Therapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Able to provide written informed consent and can understand and agree to comply with the requirements of the study and the schedule of assessments\n2. Age ≥21 years on the day of signing the ICF\n3. LA-NPC defined as AJCC\u002FUICC 8th edition TNM-stage III-IVA\n4. DETECTABLE EBV DNA levels following 3 cycles of IC, defined as \\>0 copies\u002FmL\n5. ECOG Performance Status ≤1\n6. Females of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study, and ≥120 days after the last dose of tislelizumab, and have a negative urine or serum pregnancy test ≤7 days of start of trial\n7. Non-sterile males must be willing to use a highly effective method of birth control for the duration of the study and for ≥120 days after the last dose of tislelizumab\n\nExclusion Criteria:\n\n1. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137)\n2. Has received any prior radiotherapy (RT) or systemic anti-cancer therapy including investigational agents for NPC, except for induction chemotherapy (Cisplatin and Gemcitabine) that was completed within the last 22 days. Subjects who have started on concurrent chemo-radiotherapy (CCRT; cisplatin with radiotherapy) following completion of induction chemotherapy (Cisplatin with Gemcitabine) are allowed to enroll\n3. Any known central nervous system metastases and\u002For carcinomatous meningitis\n4. Active autoimmune diseases or history of autoimmune diseases that may relapse\n\n Note: Patients with the following diseases are not excluded and may proceed to further screening:\n 1. Controlled Type I diabetes\n 2. Hypothyroidism (provided it is managed with hormone replacement therapy only)\n 3. Controlled celiac disease\n 4. Skin diseases not requiring systemic treatment (e.g., vitiligo, psoriasis, alopecia)\n 5. Any other disease that is not expected to recur in the absence of external triggering factors\n5. Any active malignancy ≤2 years before start of study except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively (e.g., resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast). Patients with a history of other malignancies may be eligible if both the Principal Investigator and the Investigator Sponsor or designee have assessed and documented that the patient has a low risk of relapse requiring no further treatment, and that participation in the clinical trial will not increase the patient's risk profile\n6. Any condition that required systemic treatment with either corticosteroids (\\>10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤14 days before start of study\n\n Note: Patients who are currently or have previously been on any of the following steroid regimens are not excluded:\n 1. Adrenal replacement steroid (dose ≤10 mg daily of prednisone or equivalent)\n 2. Topical, ocular, intra-articular, intranasal, or inhaled corticosteroid with minimal systemic absorption\n 3. Short course (≤7 days) of corticosteroid prescribed prophylactically (e.g., for contrast dye allergy) or for the treatment of a non-autoimmune condition (e.g., delayed-type hypersensitivity reaction caused by contact allergen)\n7. With uncontrolled diabetes or \\>Grade 1 laboratory test abnormalities in potassium, sodium, or corrected calcium despite standard medical management or ≥Grade 3 hypoalbuminemia ≤14 days before start of study\n8. With history of interstitial lung disease, non-infectious pneumonitis or uncontrolled diseases including pulmonary fibrosis, acute lung diseases, etc.\n9. With severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy, including tuberculosis infection, etc.\n\n 1. Severe infections within 4 weeks before start of study, including but not limited to hospitalization for complications of infection, bactiraemia, or severe pneumonia.\n 2. Received therapeutic oral or intravenous antibiotics within 2 weeks before start of study.\n10. A known history of HIV infection\n11. Patients with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers whose HBV DNA is \\>500 IU\u002FmL or patients with active hepatitis C virus (HCV) should be excluded. Note: Inactive hepatitis B surface antigen (HBsAg) carriers, treated and stable hepatitis B (HBV DNA \\\u003C500 IU\u002FmL), and cured hepatitis C patients can be enrolled\n12. Any major surgical procedure requiring general anaesthesia ≤28 days before start of study\n13. Prior allogeneic stem cell transplantation or organ transplantation\n14. Any of the following cardiovascular risk factors:\n\n 1. Cardiac chest pain, defined as moderate pain that limits instrumental activities of daily living, ≤28 days before start of study\n 2. Pulmonary embolism ≤28 days before start of study\n 3. Any history of acute myocardial infarction ≤6 months before start of study\n 4. Any history of heart failure meeting New York Heart Association (NYHA) Classification III or IV ≤6 months before start of study\n 5. Any event of ventricular arrhythmia ≥Grade 2 in severity ≤6 months before start of study\n 6. Any history of cerebrovascular accident ≤6 months before start of study\n 7. Uncontrolled hypertension: systolic pressure ≥160 mmHg or diastolic pressure ≥100 mmHg despite anti-hypertension medications ≤28 days before start of study\n 8. Any episode of syncope or seizure ≤28 days before start of study\n15. A history of severe hypersensitivity reactions to tislelizumab, gemcitabine, cisplatin, capecitabine and\u002For any of its excipients\n16. Has received any herbal medicine used to control cancer within 14 days of the start of study\n17. Patients with toxicities (as a result of prior anticancer therapy) which have not recovered to baseline or stabilized, except for AEs not considered a likely safety risk (e.g., alopecia, neuropathy and specific laboratory abnormalities)\n18. Was administered a live vaccine ≤4 weeks before start of study Note: Seasonal vaccines for influenza are generally inactivated vaccines and are allowed. Intranasal vaccines are live vaccines, and are not allowed\n19. Underlying medical conditions (including laboratory abnormalities) or alcohol or drug abuse or dependence that, will be unfavourable for the administration of study drug or affect the explanation of drug toxicity or AEs or result in insufficient or might impair compliance with study conduct\n20. Concurrent participation in another therapeutic clinical study",{"count":319,"type":23},53,[26],"Patients with \"high-risk\" locoregionally-advanced nasopharyngeal carcinoma (LA-NPC), defined as AJCC\u002FUICC 8th edition TNM-stage III-IVA and high Epstein-Barr virus (EBV) DNA viral load (≥4,000 copies\u002FmL) will require induction chemotherapy (IC) prior to chemo-radiation (CCRT) as per standard treatment. Patients who persist to manifest DETECTABLE EBV DNA following 3 cycles of IC have a higher risk of relapse, and are typically recommended for a year of low-dose oral chemotherapy after CCRT.\n\nRIBBON-LA-01 is a single-arm, open-label, phase 2 clinical trial of maintenance tislelizumab and metronomic capecitabine (metroCap) for 52 weeks after IC and CCRT, targeting this specific group of patients who have persistent detectable EBV DNA after IC. The main objective is to evaluate the efficacy of maintenance tislelizumab and metroCap in patients with DETECTABLE EBV DNA levels after 3 cycles of IC.",[323],"Nasopharyngeal Carcinoma",[325,326,327,328,329],"Locoregionally-advanced NPC","EBV DNA","Concurrent chemoradiotherapy (CCRT)","Maintenance Tislelizumab","Metronomic Capecitabine","2026-04-09",{"date":332,"type":42},"2026-04-14",{"date":334,"type":42},"2024-07-03",{"date":336,"type":23},"2029-10",{"name":48,"class":49},2,{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":12,"sex":18,"minAge":347,"maxAge":58,"enrollmentInfo":348,"targetDuration":4,"studyType":24,"phases":350,"briefSummary":351,"conditions":352,"keywords":356,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":369},"100633052","phase-2-sacituzumab-tirumotecan-in-recurrentmetastatic-adenoid-cystic-carcinoma-and-papillary-thyroid-carcinoma-strap-100633052","NCT07521670","Sacituzumab Tirumotecan in Recurrent\u002FMetastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)","A Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Patients With Recurrent\u002FMetastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP, ATLAS2501 NCCH2413\u002FMK016)","STRAP","Inclusion Criteria:\n\nCommon Eligibility Criteria for Cohorts A and B\n\n1. Unresectable locally advanced or recurrent\u002Fmetastatic adenoid cystic carcinoma or papillary thyroid carcinoma.\n2. Trophoblast cell-surface antigen 2 (TROP2) expression testing by immunohistochemistry or other methods is not required for enrollment. Provision of archival tumour tissue (where available) will be requested to support retrospective analysis. Waiver for tissue submission may be granted by the Steering Committee on a case-by-case basis if archival tissue is unavailable or insufficient for analysis.\n3. Age ≥18 years at the time of enrollment (≥21 years in Singapore)\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n5. At least one target lesion \\*identified on contrast-enhanced CT (head, neck, chest, abdomen, pelvis with ≤5 mm slice thickness) performed within 14 days prior to enrollment (same day of the week within 14 days is acceptable; this applies similarly to other time-based criteria below).\n\n \\* A non-lymph node lesion with a longest diameter of ≥10 mm or a lymph node lesion with a short axis of ≥15 mm\n6. No prior treatment with Trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugates or antibody-drug conjugates containing anti-topoisomerase I agents.\n7. Participants who have AEs due to previous anticancer therapies must have recovered to Grade ≤1 or pre-treatment baseline level (except for alopecia and vitiligo). Participants with endocrine-related AEs who are adequately treated with hormone replacement therapy are eligible.\n8. No administration of anticancer therapies (e.g., chemotherapy, targeted therapy, immunotherapy) within 13 days prior to enrollment.\n9. No major surgery under general anesthesia within 27 days prior to enrollment.\n10. No radiotherapy (including Gamma Knife or CyberKnife) within 13 days prior to enrollment. Thirteen days or fewer of palliative radiotherapy for non-CNS disease prior to enrollment is permitted. The last radiotherapy treatment must have been performed at least 7 days before enrollment.Two weeks or fewer of palliative radiotherapy for non-CNS disease is permitted. The last radiotherapy treatment must have been performed at least 7 days before the first dose of study intervention.Two weeks or fewer of palliative radiotherapy for non-CNS disease is permitted. The last radiotherapy treatment must have been performed at least 7 days before the first dose of study intervention.\n11. Laboratory values within the following criteria based on testing within 14 days prior to enrollment.\n\n 1. Neutrophil count≥1,500\u002Fmm3\n 2. Platelet count≥10x10\\^4\u002Fmm3\n 3. Hemoglobin≥9.0 g\u002FdL\n 4. AST\\\u003C100 U\u002FL\n 5. ALT\\\u003C100 U\u002FL\n 6. Total bilirubin\\\u003C1.5 mg\u002FdL\n 7. Creatinine\\\u003C1.5 mg\u002FdL, if \\>1.5 mg\u002FdL, estimated creatinine clearance ≥30 ml\u002Fmin. If an estimated value is used, it should be calculated using the Cockcroft-Gault formula.\n12. Peripheral oxygen saturation (SpO₂) ≥92% on room air within 14 days prior to enrollment.\n13. For male patients: Must agree to use acceptable contraception (refer to Notes 1,2,3) and refrain from sperm donation for at least 120 days after the last dose of study drug.\n\n For female patients: Must not be pregnant or breastfeeding and must meet one of the following conditions:\n 1. Not of childbearing potential; or\n 2. If of childbearing potential:\n\n * Agrees to use effective contraception (refer to Note 2) from the time of informed consent through at least 210 days after the last dose of study drug. If breastfeeding, agrees to discontinue breastfeeding from the first dose of the study drug through at least 10 days after the last dose.\n * Uses a contraceptive method that is highly effective (with a failure rate of \\\u003C1% per year), with low user dependency, or is abstinent from penile-vaginal intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis), as described in Appendix 19.3.2 of the study protocol during the intervention period and for at least the time needed to eliminate the study intervention after the last dose of study intervention. The participant agrees not to donate eggs (ova, oocytes) to others or freeze\u002Fstore eggs during this period for the purpose of reproduction. The length of time required to continue contraception for each study intervention is: sac-TMT: 210 days\n * The investigator should evaluate the potential for contraceptive method failure (ie, noncompliance, recently initiated) in relationship to the first dose of study intervention. Contraceptive use by POCBPs should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If the contraception requirements in the local label for any of the study interventions are more stringent than the requirements above, the local label requirements are to be followed.\n * Additional requirements for pregnancy testing during and after study intervention are in Appendix 19.3 of the study protocol\n * Medical history, menstrual history, and recent sexual activity has been reviewed by the investigator to decrease the risk for inclusion of a POCBP with an early undetected pregnancy.\n\n Note 1: The patient must not be currently pregnant and, when engaging in penile-vaginal intercourse with a partner who is capable of becoming pregnant, must use a condom (male or female type). In addition, because condoms may break or leak, the partner must also use an additional effective contraceptive method (see Appendix 19.3.3 of the study protocol).\n\n Note 2: The use of contraception must comply with local regulations regarding contraceptive practices for clinical trial participants. If local labeling requirements related to study treatment are more stringent than the above, those local requirements must be followed.\n\n Note 3: If the patient is confirmed to be azoospermic-either due to vasectomy or secondary to a medical condition-based on medical records, physical examination, or medical history as documented by site personnel, additional contraception is not required.\n14. Written informed consent obtained from the patient.\n\n Cohort A-Specific Eligibility Criteria\n15. Diagnosis of adenoid cystic carcinoma of salivary gland origin confirmed by histological examination of the primary or metastatic lesion and the diagnosis has been confirmed by central pathology review, based on pathological images of the primary or metastatic lesion (including virtual slides or low- and high-power images of H\\&E-stained specimens).\n16. No history of receiving two or more lines of systemic anticancer therapy (excluding adjuvant therapy). Due to no standard care for these patients, patients without prior systemic therapy may also be included.\n17. Tumor growth has been observed within the past 6 months.\n\n Cohort B-Specific Eligibility Criteria\n18. Diagnosis of PTC confirmed by histological examination of the primary or metastatic lesion. If this histological diagnosis was performed at the referring institution (i.e., a center not participating in the study), it must be reviewed and verified by a pathologist at the participating study site.\n19. Patients must have received at least one prior line of standard therapy for recurrent\u002Fmetastatic disease and no more than two prior lines (RAI therapy is not counted as a prior line).\n\nExclusion Criteria:\n\n1. Active central nervous system (CNS) metastases - including brain metastases, carcinomatous (leptomeningeal) meningitis, or symptomatic spinal metastases that require radiotherapy or surgical intervention. However, patients with previously treated brain metastases may be enrolled if imaging performed at screening shows radiographic stability for at least 28 days with no evidence of progression, they are clinically stable, and they have not required steroid therapy for at least 14 days before enrollment.\n2. Clinically significant pericardial effusion, pleural effusion, or ascites requiring treatment.\n3. Has a current and past history of documented severe dry eye syndrome, severe Meibomian gland disease and\u002For blepharitis, or severe corneal disease that prevents\u002Fdelays corneal healing.\n4. Has uncontrolled, significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QTcF interval to \\>480 ms, prior treatment history with cardiotoxic agents and\u002For other serious cardiovascular and cerebrovascular diseases within 6 months before enrollment.\n5. Received a live or live-attenuated vaccine within 30 days before enrollment. Administration of inactivated vaccines are allowed.\n6. Is currently receiving a strong inducer\u002Finhibitor of CYP3A4 that cannot be discontinued for the duration of treatment with study intervention. The required washout period before starting study intervention is 2 weeks.\n\n Note: A list of strong inducers\u002Finhibitors of CYP3A4 can be found at the following website: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-interactions-labeling\u002Fdrug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Please note that this list is not exhaustive and that investigators should review the locally-approved label for all concomitant therapy to ensure it is not a strong inducer\u002Finhibitor of CYP3A4.\n7. Is currently participating in another therapeutic clinical trial. Concurrent enrollment on another therapeutic clinical trial or any trial designed to impact the efficacy of anti-cancer therapy is prohibited.\n8. Has received an investigational agent or has used an investigational device within 28 days before enrollment.\n9. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.\n\n Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (excluding carcinoma in situ of the bladder) who have undergone potentially curative resection are not excluded.\n\n Note: Participants with low-risk early-stage prostate cancer (T1-T2a, Gleason score ≤6, and PSA \\\u003C10 ng\u002FmL) either treated with definitive intent or untreated in active surveillance with stable disease are not excluded.\n10. Has an active infection requiring systemic therapy except those permitted in the exclusion criteria 15), 16), and 17) (e.g., HIV, HBV, HCV)\n11. Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study, interfere with the individual's ability to cooperate with the requirements of the study, or interfere with the individual's participation for the full duration of the study, such that it is not in the best interest of the individual to participate, in the opinion of the treating investigator.\n12. Severe hypersensitivity (Grades ≥3) to study intervention, any of their excipients, and\u002For to another biologic therapy.\n13. Has had major surgery or significant traumatic injury within 27 days before enrollment. Anticipation of the need for major surgery during the course of treatment with study intervention is also exclusionary.\n\n Note: Participants who underwent major surgery must have adequately recovered from toxicity and\u002For complications from the surgery before starting study intervention.\n14. Has a history of (noninfectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease.\n15. Participants with HIV infection will be excluded unless all of the following conditions are met:\n\n 1. Having a CD4+ T-cell count ≥350 cells\u002Fmm3 at the time of screening\n 2. Having achieved and maintained virologic suppression, defined as confirmed HIV RNA level below 50 or the LLOQ using the locally available assay, at the time of screening and for at least 12 weeks before screening\n 3. Absence of any AIDS-defining opportunistic infections within the past 12 months\n 4. Being on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks before registration and agreeing to continue ART throughout the study Note: The ART regimen must not contain any antiretroviral medications that are strong CYP3A4 inducers\u002Finhibitors\u002Fsubstrates. Refer to https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-interactions-labeling\u002Fdrug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Please note that this list is not exhaustive and that investigators should review the locally-approved label for all concomitant therapy to ensure it is not a strong inducer\u002Finhibitor\u002Fsubstrate of CYP3A4.\n16. Positive for HCV RNA, or, if HCV RNA is negative, has not completed curative antiviral therapy at least 28 days prior to enrollment. HCV RNA testing is required only for patients who test positive for HCV antibodies or as mandated by local regulations.\n17. Positive for HBs antigen, or negative for HBs antigen but positive for either HBs antibody or HBc antibody and positive for HBV DNA quantification. Patients are eligible if HBV DNA is below the lower limit of quantification; however, they will be excluded if they have not received at least 4 weeks of antiviral therapy prior to enrollment.\n18. Patients with active gastrointestinal ulcers.","18 Years",{"count":349,"type":23},68,[26],"This is an open-label, investigator-initiated phase II clinical trial designed to evaluate the efficacy and safety of Sacituzumab Tirumotecan (sac-TMT) monotherapy in patients with recurrent or metastatic adenoid cystic carcinoma (ACC) of salivary gland origin and papillary thyroid carcinoma (PTC). A total of 68 patients will be enrolled over in 18-month period, with 34 patients in Cohort A (ACC) and 34 in Cohort B (PTC). All participants will receive sac-TMT at a dose of 4 mg\u002Fkg administered intravenously on Days 1 and 15 of each 28-day cycle.\n\nThe primary endpoint is the objective response rate (ORR), defined as the proportion of patients achieving a complete or partial response as assessed by the site investigators. Secondary endpoints include progression-free survival, overall survival, disease control rate, safety and tolerability, dose intensity, and relative dose intensity.",[353,354,355],"Recurrent Adenoid Cystic Carcinoma","Adenoid Cystic Carcinoma Metastatic","Papillary Thyroid Carcinoma",[357,358,359,360,355],"Sacituzumab Tirumotecan","Recurrent","Metastatic","Adenoid Cystic Carcinoma","2026-04-07",{"date":363,"type":42},"2026-04-13",{"date":365,"type":23},"2026-05",{"date":367,"type":23},"2028-10-31",{"name":48,"class":49},7,{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":58,"enrollmentInfo":378,"targetDuration":4,"studyType":24,"phases":380,"briefSummary":381,"conditions":382,"keywords":384,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":82},"100461269","phase-2-phase-ii-lenvatinib-and-pembrolizumab-in-endocrine-resistant-breast-cancer-with-letrozole-100461269","NCT05286437","Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole","Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole in the Advanced Setting - a Phase II Study","LaPemERLA","Inclusion Criteria:\n\n1. Male\u002Ffemale participants who are at least 21 years of age on the day of signing informed consent, with histologically or cytologically confirmed diagnosis of metastatic or locally advanced carcinoma of the breast not amenable to treatment with curative intent, will be enrolled in this study.\n2. Disease progression after treatment with at least 1 line of palliative endocrine therapy in the metastatic setting.\n\n 1. There is no limit to the number of lines of prior palliative endocrine therapy. (Prior aromatase inhibitor in the curative and\u002For palliative setting is allowed.)\n 2. Prior targeted therapy in the locally advanced (recurrent or progressed) or metastatic setting, such as CDK4\u002F6 inhibitors, mTOR inhibitors, PI3K inhibitors, is allowed with no limit to the number of lines of targeted therapy (prior Lenvatinib is not allowed).\n 3. Maximum of 1 line of palliative chemotherapy is allowed.\n\n * A chemotherapy line in advanced disease is an anticancer regimen(s) that contains at least 1 cytotoxic chemotherapy agent and was discontinued due to progression. If a cytotoxic chemotherapy regimen was discontinued for a reason other than disease progression then this regimen does not count as a \"prior line of chemotherapy\".\n * Antibody-drug conjugate will be considered as cytotoxic chemotherapy in the assessment of the lines of treatment.\n3. ER positive and\u002For PgR positive breast cancer (based on most recent tumor biopsy or archived tumor specimen) according to American Society of Clinical Oncology\u002FCollege of American Pathologists (ASCO\u002FCAP) guidelines, assessed locally and defined as at least 1% of tumor cells stained positive.\n4. HER2-negative tumor assessed locally and defined as meeting one of the following sets of criteria:\n\n * HER2 IHC score of 0 or 1+\n * HER2 IHC score of 2+ accompanied by a negative fluorescence, chromogenic, or silver in situ hybridization test indicating the absence of HER2 gene amplification\n * HER2\u002FCEP17 ratio of \\\u003C 2.0 based on the most recent tumor biopsy (or archived tumor sample).\n5. For women: postmenopausal or premenopausal\u002Fperimenopausal status, defined as follows: Postmenopausal, as defined by at least one of the following criteria:\n\n * Age ≥ 60 years\n * Age \\\u003C 60 years and ≥ 12 months of amenorrhea plus follicle-stimulating hormone (FSH) and plasma estradiol levels within postmenopausal range by local laboratory assessment, in the absence of oral contraceptive pills, hormone replacement therapy, or gonadotropin-releasing hormone agonist or antagonist\n * Documented bilateral oophorectomy (≥14 days prior to first treatment on Day 1 of Cycle 1 and recovery from surgery to baseline) Premenopausal or perimenopausal, defined as not meeting the criteria for postmenopausal, and willing to undergo and maintain treatment with approved LHRH-agonist therapy for the duration of study treatment LHRH-agonist therapy may be initiated 14-28 days prior to commencement of letrozole, and continued 4-weekly.\n\n For men: willing to undergo and maintain treatment with approved LHRH-agonist therapy for the duration of study treatment; LHRH-agonist therapy may be initiated 14-28 days prior to commencement of letrozole, and continued 4-weekly.\n6. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n 1. Not a woman of childbearing potential (WOCBP) as defined in protocol OR\n 2. A WOCBP who agrees to follow the contraceptive guidance in protocol during the treatment period and for at least 120 days (corresponding to time needed to eliminate pembrolizumab and\u002For any active comparator\u002Fcombination) plus 30 days (a menstruation cycle) after the last dose of study treatment.\n7. A male participant must agree to use a contraception during the treatment period and for at least 120 days, corresponding to time needed to eliminate pembrolizumab plus an additional 90 days (a spermatogenesis cycle) after the last dose of study treatment and refrain from donating sperm during this period.\n8. The participant provides written informed consent for the trial.\n9. Have measurable disease based on RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.\n10. Availability of tumor sample:\n\n * Patient should have a site of disease amenable to biopsy, and be a candidate for tumor biopsy according to the treating institutions guidelines. Patient must be willing to undergo a new tumor biopsy at screening. Bone metastases are not acceptable.\n * A representative tumor sample obtained after progression on the patients most recent endocrine therapy must be submitted\n * In the event that a post-progression sample is not available and a new biopsy cannot be obtained, enrolment may be considered after documented discussion with the Principal Investigator and the study team for a waiver.\n11. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 7 days prior to the first dose of study intervention.\n12. Life expectancy of more than 12 weeks.\n13. Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤150\u002F90 mmHg at screening and no change in antihypertensive medications within 1 week prior to the Cycle 1 Day -14.\n14. Have adequate organ and haematological functions as defined in the protocol.\n\nExclusion Criteria:\n\n1. A WOCBP who has a positive urine pregnancy test within 72 hours prior to allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n\n Note: in the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for subject to start receiving study medication.\n2. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).\n3. Has received prior Lenvatinib.\n4. Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks (or 5 times the half-life, whichever is shorter) prior to allocation. Note: Participants must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline. Participants with ≤Grade 2 neuropathy may be eligible. Participants with endocrine-related AEs Grade ≤2 requiring treatment or hormone replacement may be eligible.\n5. Lack of adequate recovery from any toxicity and\u002For complications from any toxicity and\u002For complications from major surgery prior to starting therapy.\n6. Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.\n7. Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of study drug. Administration of killed vaccines is allowed.\n8. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks (or 5 times the half-life for systemic agent(s), whichever is shorter) prior to the first dose of study intervention.\n9. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.\n10. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.\n11. Has known active CNS metastases and\u002For carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study intervention.\n12. Has severe hypersensitivity (≥Grade 3) to Pembrolizumab, Lenvatinib, Letrozole and\u002For any of its excipients.\n13. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed. Subjects with T3, free T3 or free T4 abnormalities at screening who are asymptomatic can be eligible, but will need to be monitored closely with correction of abnormalities as clinically indicated.\n14. Has a history of (non-infectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease.\n15. Subjects having \\>1+ proteinuria on urinalysis will undergo 24-hour urine collection for quantitative assessment of proteinuria. Subjects with urine protein ≥1 g\u002F24-hour will be ineligible.\n16. Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of Lenvatinib.\n17. New York Heart Association congestive heart failure of grade II or above, unstable angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia associated with significant cardiovascular impairment within the past 6 months.\n18. Prolongation of QTc interval to \\>480 msec.\n19. Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug.\n20. Serious nonhealing wound, ulcer, or bone fracture\n21. Has an active infection requiring systemic therapy. Hepatitis B and\u002For C infection may be allowed if controlled (see criterion 23 below).\n22. Has a known history of Human Immunodeficiency Virus (HIV) infection. Note: No HIV testing is required unless mandated by local health authority.\n23. Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV RNA \\[qualitative\\] is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority. The presence of hepatitis B core antibody (HBcAb) will not be an exclusion criterion provided HBsAg is negative and Hepatitis B virus DNA is not detected.\n24. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n25. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n26. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.\n27. Has had an allogenic tissue\u002Fsolid organ transplant.",{"count":379,"type":23},40,[26],"This is a phase II study testing the combination of Pembrolizumab with Lenvatinib, a multi-kinase inhibitor that has activity against vascular endothelial growth factor receptors 1-3 (VEGFR1-3), fibroblast growth factor receptors 1-4 (FGFR1-4), ret protooncogene (RET), platelet-derived growth factor receptor-alpha (PDGFR-alpha) and KIT (a stem cell factor receptor), and letrozole, a non-steroidal aromatase inhibitor, in advanced hormone receptor (HR) positive human epidermal growth factor receptor 2 (HER2) negative breast cancer (BC) that has progressed on\u002Fafter standard endocrine therapy.",[383],"Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer",[385],"Advanced Breast Cancer","2026-03-31",{"date":388,"type":42},"2026-04-06",{"date":390,"type":42},"2023-02-15",{"date":392,"type":23},"2028-12-31",{"name":48,"class":49},{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":58,"enrollmentInfo":402,"targetDuration":4,"studyType":24,"phases":403,"briefSummary":404,"conditions":405,"keywords":407,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":418},"100625878","histotripsy-for-ablation-of-liver-tumours-in-asia-100625878","NCT07428356","Histotripsy for Ablation of Liver Tumours in Asia","Histotripsy Ablation for Liver Tumours (HALT): A Multi-centre Prospective Pilot Study on the Safety and Efficacy of Histotripsy in Asian Primary and Secondary Liver Malignancies","HALT","Inclusion Criteria:\n\n1. Age ≥21 years at the time of consent.\n2. Histologically\u002Fcytologically confirmed cancers (imaging diagnosis as per AASLD allowed for HCC):\n\n A) Liver limited malignancies (primary or secondary) not eligible for\u002Fdeclined resection or other locoregional treatment modalities.\n\n B) All solid cancer patients (e.g., HCC, colorectal, breast, pancreatic cancers etc) undergoing systemic therapy with oligoprogressive liver disease (defined as ≤ 3 liver limited progressive lesions, ≤ 3 cm in maximum diameter having received \\> 3 months of systemic therapy).\n3. Characteristics of hepatic lesions intended for treatment:\n\n * Up to 3 hepatic lesions.\n * Tumour ≤ 3 cm in longest diameter.\n * Lesion(s) must be visible and targetable by ultrasound.\n4. ECOG Performance Status 0-1.\n5. Child-Pugh class A or B7 liver function for patients with underlying cirrhosis.\n6. Adequate hematologic and organ function within 14 days prior to treatment:\n\n * Haemoglobin ≥ 9.0 g\u002FdL\n * Platelets ≥ 75,000\u002Fmm³\n * INR ≤ 1.5 × ULN\n * Estimated (by Cockroft-Gault or Modification of Diet in Renal Disease (MDRD) or measured creatinine clearance ≥ 50ml\u002Fmin.\n * Total bilirubin ≤ 1.5 × upper limit normal or direct bilirubin ≤ ULN for participants with total bilirubin \\> 1.5 × ULN (participants with known history of elevated indirect bilirubin level suggestive of extrahepatic source of elevation e.g. Gilbert's disease may be recruited with bilirubin levels ≤ 3 × ULN)\n * AST and ALT ≤ 5 × ULN\n7. Ability to undergo general anaesthesia, as confirmed by pre-anaesthetic assessment.\n8. Life expectancy ≥ 3 months in the opinion of the investigator.\n9. Willing and able to comply with study visits and procedures.\n10. Written informed consent obtained prior to any study-related procedures.\n\nExclusion Criteria:\n\n1. Extrahepatic disease progression requiring immediate systemic intervention, including new brain metastases or malignant ascites.\n2. Vascular invasion, defined as gross involvement or encasement of major portal vein or hepatic vein branches.\n3. Tumours located adjacent (\\\u003C5 mm) to hollow viscera (e.g., stomach, colon) where histotripsy poses perforation risk.\n4. Lesions poorly visualized on ultrasound or not targetable due to overlying ribs or gas.\n5. Severe or uncontrolled comorbidities including:\n\n * Uncontrolled hypertension or cardiovascular disease\n * Active infection (requiring systemic therapy)\n * Severe chronic obstructive pulmonary disease or hypoxia\n6. Contraindications to general anaesthesia or surgery.\n7. Pregnancy or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 7 days prior to treatment.\n8. Participation in another interventional trial within 4 weeks prior to enrollment, or concurrent participation in a therapeutic study.\n9. Any condition that, in the investigator's judgment, may compromise the patient's safety or interfere with protocol adherence.",{"count":379,"type":23},[94],"The HALT study aims to evaluate histotripsy in an Asian population for both primary (HCC, CCA) and secondary liver malignancies with liver-limited or oligoprogressive disease. In addition to safety and local control, the study incorporates translational endpoints including immune profiling (PBMCs, cytokines), microbiome shifts, and optional tumour biopsies. This trial will provide critical data on the feasibility, tolerability, and biological impact of histotripsy in a region with the highest burden of liver cancer.",[406],"Liver Malignant Tumors",[408,409],"Histotripsy","Ablation of Liver Tumours","2026-02-19",{"date":412,"type":42},"2026-02-23",{"date":414,"type":42},"2025-11-07",{"date":416,"type":23},"2029-05-07",{"name":48,"class":49},3,{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":12,"sex":18,"minAge":168,"maxAge":58,"enrollmentInfo":427,"targetDuration":4,"studyType":24,"phases":429,"briefSummary":430,"conditions":431,"keywords":434,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":338},"100610959","sensory-enrichment-using-aromatherapy-for-neurobehavioral-and-psychological-symptoms-in-early-dementia-100610959","NCT07234357","Sensory Enrichment Using Aromatherapy for Neurobehavioral and Psychological Symptoms in Early Dementia","Sensory Enrichment Using Aromatherapy for Neurobehavioral and Psychological Symptoms in Early Dementia (SENSE)","SENSE","Inclusion Criteria:\n\nFor patients:\n\n* Aged 50 years old and above.\n* Confirmed diagnosis of MCI or mild dementia based on clinical records.\n* Has one identified caregiver aged 21 years and above who is willing to provide written informed consent for his\u002Fher own participation; is able to read, understand, and speak the designated language at the study site; either lives with the subject or sees the subject for ≥2 hours\u002Fday ≥3 days\u002Fweek; agrees to accompany the subject to each study visit; and is able to verify daily compliance with study intervention.\n\nFor caregivers:\n\n* Aged 21 years old and above.\n* Willing and able to provide written informed consent\n* Identified as the caregiver for recruited patient in this study can read, understand, and speak the designated language at the study site; either lives with the recruited patients or sees the patient for ≥2 hours\u002Fday ≥3 days\u002Fweek.\n* Agrees to accompany the patient to each study visit; and can verify daily compliance with study intervention.\n\nExclusion Criteria:\n\nFor patients:\n\n* Olfactory impaired\u002Fdysfunctional.\n* Known or suspected hypersensitivity\u002Fallergy to essential oils or any components of the formulations.\n* Has Reactive Airway Disease (e.g, Asthma).\n* Participant without a caregiver.\n* Pregnant, breastfeeding, or intending to conceive during study period.\n\nFor caregivers:\n\n* Physically or mentally incapable of providing verbal \u002F written consent\n* Does not have regular or meaningful contact with the participant (e.g. less than 2 hours\u002Fday or less than 3 days\u002Fweek).\n* Not able to follow patient to each study visit.",{"count":428,"type":23},200,[94],"To determine if diffusion aromatherapy exposure to an essential oil blend can potentially improve mild cognitive impairment\u002Fmild dementia symptoms and relieve caregiver stress.\n\nThis study also allows us to gauge the willingness of elderly patients in complying with long-term aromatherapy treatments.",[432,433],"Mild Cognitive Impairment","Mild Dementia",[435,436,437,438,433,439,440,441,442,443],"Aromatherapy","Diffusion Aromatherapy","Essential Oils","Mild Cognitive Impairment (MCI)","Dementia","Caregiver Burden","Caregiver Stress","Elderly Compliance","Caregiver","2025-11-14",{"date":446,"type":42},"2025-11-18",{"date":448,"type":23},"2025-11",{"date":450,"type":23},"2026-11",{"name":48,"class":49},{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":458,"eligibilityCriteria":459,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":58,"enrollmentInfo":460,"targetDuration":4,"studyType":24,"phases":461,"briefSummary":462,"conditions":463,"keywords":465,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":140},"100468227","phase-2-multinational-phase-ii-trial-to-compare-safety-and-efficacy-of-sirt-y-90-resin-microspheres-followed-by-atezolizumab-plus-bevacizumab-vs-sirt-sirt-y90-followed-by-placebo-in-locally-advanced-hcc-patients-100468227","NCT05377034","Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients","A Multinational, Double-blind, Placebo-Controlled, Parallel Randomized Arms, Phase II Trial to Compare Safety and Efficacy of Selective Internal Radiation Therapy (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab) Versus Selective Internal Radiation Therapy (SIRT-Y90) Followed by Placebo in Patients With Locally Advanced Hepatocellular Carcinoma (HCC)","STRATUM","Inclusion Criteria:\n\nPatients must fulfill all of the following criteria to be eligible for this study:\n\n1. Unequivocal diagnosis of HCC (AASLD 2010 diagnostic criteria or histology) that is locally advanced without extra-hepatic metastases but with significant tumor burden, i.e.,\n\n * Tumor confined to the liver that is beyond the up-to-7 criteria, and\u002For\n * Tumor with vascular invasion VP 1-3 and\u002For Vv 1-2 (at the discretion of site investigator) Both local and central assessments are required at screening, prior to any study treatment. Sites are required to send all CT\u002FMRI images for central imaging review. The central assessment result will be made known to sites and will take precedence in determining a patient's study eligibility in case of a discrepancy between local and central review.\n2. Aged 21 years old and above of either gender.\n3. Patient eligible for SIRT-Y90 treatment after assessment with macro-aggregated albumin labeled with technetium-99 (Tc-99m MAA) scan on SPECT\u002FCT or planar imaging with all of the following criteria prior to each SIRT-Y90 treatment:\n\n * Lung shunting \\\u003C20% on SPECT\u002FCT or planar imaging\n * Lung dose limit of \\\u003C25Gy for single treatment or \\\u003C30Gy for cumulative treatment (second delivery within 4-6 weeks)\n4. No prior radiation to the liver.\n5. No prior systemic adjuvant or neoadjuvant therapy for HCC.\n6. Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥10 mm with spiral CT scan or MRI.\n7. Negative HIV test at screening, with the following exception - patients with a positive HIV test at screening are eligible provided they fulfil all of the following criteria:\n\n * Are stable on anti-retroviral therapy\n * Have a CD4 count ≥ 200\u002FμL\n * Have an undetectable viral load\n8. Documented virology status of hepatitis, as confirmed by screening hepatitis B virus (HBV) and hepatitis C virus (HCV) tests.\n9. Patients with active HBV: HBV DNA \\\u003C3000 IU\u002FmL, initiation of anti-HBV treatment at least 14 days prior to randomization, and willingness to continue anti-HBV treatment during the study (per local standard of care; e.g., entecavir).\n\n For patients with HBV DNA ≥ 500 IU\u002FmL during screening, anti-HBV treatment will be initiated and HBV DNA levels will be re-assessed prior to randomization.\n10. ECOG performance status 0 - 1.\n11. Child-Pugh A (up to 6 points).\n12. Adequate hematological, renal, and hepatic function as follows:\n\n * Lymphocyte count ≥ 0.5 x 10\\*\\*9\u002FL (500\u002FμL)\n * Platelets ≥75,000\u002FμL without transfusion\n * Hemoglobin \\>9.5 g\u002FdL (Patients may be transfused to meet this criterion.)\n * Serum bilirubin ≤ 3 x ULN\n * For patients not receiving therapeutic anticoagulation: INR and aPTT ≤ 2.0 x ULN\n * ALP ≤5×institutional upper limit of normal\n * AST and ALT ≤5×institutional upper limit of normal\n * Albumin ≥2.8 g\u002FdL\n * Serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 30 mL\u002Fmin (calculated using the Cockcroft-Gault formula)\n * Absolute Neutrophil Count ≥1.5×10\\*\\*9\u002FL without granulocyte colony-stimulating factor support\n * Urine dipstick for proteinuria \\\u003C2+ at screening\n\n * Patients discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate \\\u003C1g of protein in 24 hours\n13. Life expectancy of at least 3 months without any active treatment.\n14. Suitable for protocol treatment as determined by clinical assessment undertaken by the site investigator.\n15. Performance of an esophagogastroduodenoscopy (EGD) within 6 months prior to randomization as part of pre-procedure work-up or during screening, and assessment and complete treatment of varices of all sizes per local standard of care prior to randomization.\n\n Patients with varices should be re-assessed prior to randomization to ensure complete treatment of varices of all sizes per local standard of care.\n16. Willing, able and mentally competent to provide written informed consent prior to any testing undertaken for this study protocol, including screening tests and evaluations that are not considered to be part of the patient's routine care.\n17. Female patients must be either postmenopausal or, if premenopausal, must have a negative pregnancy test and agree to use two forms of contraception if sexually active during the treatment period, for at least 5 months after the last dose of atezolizumab and 6 months after the last dose of bevacizumab.\n18. Male patients must be surgically sterile, or if sexually active and having a pre-menopausal female partner, they must be using an acceptable form of contraception during the treatment period and for 6 months after the last dose of bevacizumab.\n\nExclusion Criteria:\n\nThe following criteria should be checked. If ANY apply, the patient must not be included in the study:\n\n1. Patient not eligible for SIRT-Y90 treatment after assessment with macro-aggregated albumin labeled with technetium-99 (MAA) scan on SPECT\u002FCT or planar imaging.\n2. Patients who have SAE \\> grade 3 within 4 weeks after receiving SIRT-Y90. For patients who experience SAE \\> grade 3 after receiving SIRT-Y90 (1st or 2nd administration), the duration between the SIRT-Y90 dose and randomization and\u002For 1st and 2nd SIRT-Y90 dose (for two-staged delivery) may be extended by an additional 4 weeks to re-assess the patient's eligibility.\n3. Patients who have had \\>2 administrations of hepatic artery directed therapy.\n4. Patients who have had hepatic artery directed therapy done \\\u003C4 weeks prior to date of ICF signing.\n5. Patients who have had systemic adjuvant or neoadjuvant therapy for HCC.\n6. Prior hepatic radiation therapy for HCC or other malignancy.\n7. Patient who has received any immunotherapy (including interferon-alfa, peginterferon alfa-2a, peginterferon alfa-2b, thymosin-α1, etc.) within 30 days prior to randomization, is currently receiving immunotherapy or is planned to start immunotherapy during the study (e.g., for the management of active CHB or CHC according to local guidelines).\n8. Has evidence that \\\u003C30% of the total liver volume is disease-free.\n9. Currently receiving any other investigational agents for the treatment of their cancer.\n10. Has intractable clinical ascites (in spite of optimal diuretic treatment) or any other clinical signs of liver failure, on physical examination.\n11. Untreated or incompletely treated esophageal and\u002For gastric varices prior to randomization.\n12. Presence of tumor thrombus in the main trunk of the portal vein or a portal vein branch contralateral to the primarily involved lobe (or both) i.e. beyond VP3 and\u002For tumor thrombus in the inferior vena cava or right atrium i.e. beyond Vv2.\n13. Any metastatic disease i.e. lymph node ≥15 mm in short axis or distant metastasis.\n14. Any other concurrent malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for at least five years.\n15. Presence of clinical signs of CNS metastases due to their poor prognosis and because progressive neurologic dysfunction would confound the evaluation of neurologic and other adverse events.\n16. Uncontrolled inter-current illness including, but not limited to, ongoing or active infection (except viral hepatitis), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n17. Inadequately controlled arterial hypertension (defined as systolic blood pressure \\[BP\\]\\>150 mmHg and\u002For diastolic BP \\>100 mmHg), based on an average of at least three BP readings on separate occasions.\n\n • Anti-hypertensive therapy to achieve these parameters is allowed.\n18. Any of the following contraindications to angiography and selective visceral catheterization:\n\n * Bleeding diathesis, not correctable by the standard forms of therapy.\n * Severe peripheral vascular disease that would preclude arterial catheterization.\n19. Significant cardiovascular disease (such as cardiac disease, myocardial infarction, or cerebrovascular accident within 3 months prior to randomization), unstable arrhythmia, or unstable angina.\n20. History of congenital long QT syndrome or corrected QT interval \\> 500 ms (calculated with use of the Fridericia method) at screening\n21. History of uncorrectable electrolyte disorder affecting serum levels of potassium, calcium, or magnesium\n22. Current or recent use (within 10 days prior to angiogram) of aspirin (\\>325 mg\u002Fday) or current or recent treatment with dipyridamole, ticlopidine, clopidogrel, and cilostazol.\n\n • Use of dipyridamole, ticlopidine, clopidogrel, and cilostazol is allowed for patients who do not have any active bleeding for the past 6 months after review with attending physician.\n23. Current or recent (within 10 days prior to angiogram) use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purpose.\n\n * Prophylactic anticoagulation for the patency of venous access devices is allowed provided the activity of the agent results in an INR \\\u003C1.5×ULN and aPTT is within normal limits (according to institutional standards) within 14 days prior to Day 1 of Cycle 1.\n * Prophylactic use of low-molecular-weight heparin (i.e., enoxaparin 40 mg\u002Fday) is allowed. However, the use of direct oral anticoagulant therapies such as dabigatran (Pradaxa®) and rivaroxaban (Xarelto®) is not recommended due to bleeding risk.\n24. History of allergic reactions attributed to compounds of similar chemical or biologic composition to SIRT-Y90 or atezolizumab or bevacizumab.\n25. The patient has active or history of autoimmune disease or immune deficiency such as, but not limited to, multiple sclerosis, systemic lupus erythematosus, and inflammatory bowel disease, with the following exceptions:\n\n * Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study.\n * Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.\n * Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:\n\n * Rash must cover \\\u003C 10% of body surface area\n * Disease is well controlled at baseline and requires only low-potency topical corticosteroids\n * No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months prior to screening.\n26. The patient requires concomitant treatment with any immunosuppressive or immunostimulant agent, or with systemic corticosteroids prescribed for chronic treatment (more than 7 consecutive days).\n27. Inability or unwillingness to understand or sign a written informed consent document.\n28. Female patients who are pregnant or currently breastfeeding.\n29. Current enrolment in any other investigational therapeutic drug or device study.",{"count":92,"type":23},[26],"This is a multi-national, phase II, parallel-arm, double-blind, placebo-controlled, two-arm study designed to assess the efficacy and safety of SIRT-Y90 followed by atezolizumab plus bevacizumab \\[study arm\\], versus SIRT-Y90 followed by placebo \\[control arm\\] in patients with locally advanced Hepatocellular Carcinoma (HCC).",[464],"Locally Advanced Hepatocellular Carcinoma",[466,467,29,468],"SIRT-Y90","Atezolizumab plus Bevacizumab","SIR-Sphere","2025-09-30",{"date":471,"type":42},"2025-10-06",{"date":473,"type":42},"2022-10-26",{"date":475,"type":23},"2028-01-31",{"name":48,"class":49},{"id":478,"slug":479,"hasResults":12,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":4,"eligibilityCriteria":483,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":484,"targetDuration":4,"studyType":24,"phases":486,"briefSummary":487,"conditions":488,"keywords":493,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":82},"100432565","phase-2-neoantigen-dendritic-cell-vaccine-and-nivolumab-in-hcc-and-liver-metastases-from-crc-100432565","NCT04912765","Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC","An Open Label, Single-arm, Phase II Neoantigen (NA) Dendritic Cell (DC) Vaccine and Anti-PD1 (Nivolumab) as Adjuvant Treatment in Resected Hepatocellular Carcinoma (HCC) (Group A) and Liver Metastases From Colorectal Cancer (CRLM) (Group B)","Inclusion Criteria:\n\nHCC specific criteria (Group A):\n\n* Participants must have either newly diagnosed or recurrent HCC, confirmed by histology\u002Fcytology or clinically by AASLD criteria in cirrhotic subjects amenable for management with curative intent by resection (with or without the addition of local ablation), if they fulfil the following radiological criteria.\n\n 1. Up to three tumours, at least one with a diameter \\> 3cm\n 2. More than three tumours, none with a diameter \\> 5 cm\n 3. Recurrent HCCs are permitted if they were previously treated with curative intent (e.g. by surgery or ablative methods) and with liver-limited recurrence fulfilling criteria (a) and (b)\n* Child-Pugh Score 5 or 6\n* All participants are required to have imaging studies (CT chest, tri-phasic CT\u002FMRI of the liver, contrast-enhanced CT\u002FMRI of abdomen and pelvis and other suspected\u002Fknown sites of disease, and bone scans if indicated) confirming no-extra-hepatic metastatic disease within 12 weeks prior to study enrolment.\n\nCRLM specific criteria (Group B):\n\n* Patients with histologically- or cytologically-diagnosed colorectal cancer with liver-limited metastases are eligible to enrol if:\n\n 1. There are no other sites of metastases aside from the liver confirmed by imaging studies (contrast-enhanced CT chest, abdomen and pelvis or contrast-enhanced CT chest and MRI abdomen and pelvis and other suspected sites of disease, and bone scans if indicated) at least 12 weeks prior to study enrolment AND\n 2. The liver metastases are amenable and planned for curative surgical resection with or without the addition of local ablation AND\n 3. The primary colorectal tumour had previously been resected or is amendable and planned for surgical resection.\n* Participants must have received peri-operative chemotherapy or are being planned for adjuvant chemotherapy after curative surgical resection\n* Participants with rectal cancer who received neoadjuvant radiation or are planned for adjuvant radiation are allowed into the study.\n\nGeneral Inclusion Criteria:\n\n* Participants are eligible to enroll if they have non-viral related-HCC, or if they have HBV-HCC, or HCV-HCC defined as follows:\n\n 1. Non-HBV non-HCV related HCC\n 2. HBV-HCC:\n\n 1. Resolved HBV infection (as evidenced by detectable HBV surface antibody, detectable HBV core antibody, undetectable HBV DNA, and undetectable HBV surface antigen), OR\n 2. Chronic HBV infection as evidenced by detectable HBV surface antigen or HBV DNA. Participants with chronic HBV infection must be on antiviral therapy\n 3. HCV-HCC:\n\n 1. Resolved HCV infection as evidenced by detectable antibody, OR\n 2. Chronic HCV infection as evidenced by detectable HCV RNA.\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1\n* Screening laboratory values must meet the following criteria, and should be obtained within 28 days prior to study enrolment:\n\n 1. Adequate hematologic function:\n\n 1. WBC ≥ 2,000\u002FμL (stable, off any growth factor within 4 weeks of study treatment administration);\n 2. Neutrophils Absolute ≥ 1,500\u002FμL (stable, off any growth factor within 4 weeks of study treatment administration);\n 3. Hemoglobin ≥ 8.5 g\u002FdL (may be transfused to meet this requirement);\n 4. Platelet count ≥ 60 × 103\u002FμL (transfusion to achieve this level is not permitted);\n 2. Adequate hepatic function:\n\n 1. Serum albumin \\> 2.8 g\u002FL (transfusion to meet this level is not permitted); and\n 2. Serum total bilirubin \\\u003C 3 mg\u002FdL, and\n 3. Serum Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 5 × ULN;\n 3. Prothrombin time (PT)-international normalized ratio (INR) \\\u003C 2.3 or Prothrombin time (PT) \\\u003C 6 seconds (transfusion to achieve this level is not permitted)\n 4. Adequate renal function with a serum creatinine of \\\u003C 1.5 × ULN or a creatinine clearance \\> 40 mL\u002Fmin (Cockcroft-Gault formula)\n* Age and Reproductive Status:\n\n 1. Males and females, ages 21 or older.\n 2. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 24 hours prior to the start of study treatment.\n 3. Women must not be breastfeeding.\n 4. WOCBP must agree to follow instructions for method(s) of contraception (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, or condom with spermicide, or abstinence) for the duration of study treatment with nivolumab and 7 months after the last dose of study treatment.\n 5. Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, or condom with spermicide, or abstinence) for the duration of study treatment with nivolumab and 7 months after the last dose of study treatment. In addition, male participants must be willing to refrain from sperm donation during this time.\n 6. Azoospermic males are exempt from contraceptive requirements. WOCBP who are continuously not heterosexually active are also exempt from contraceptive requirements, and still must undergo pregnancy testing as described in this section.\n\nExclusion Criteria:\n\nHCC specific criteria (Group A):\n\n* Target Disease Exceptions\n\n 1. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.\n 2. Any evidence of tumour metastasis or co-existing malignant disease.\n 3. Participants showing evidence of macrovascular invasion on imaging tests.\n 4. Participants who have undergone a liver transplant or those who are in the waiting list for liver transplantation.\n 5. Participants previously receiving any prior systemic therapy, trans-arterial embolization or chemoembolisation (TAE\u002FTACE), selective internal radiation therapy (SIRT) and stereotactic radiation therapy (SBRT) for HCC.\n\n CRLM specific criteria (Group B)\n* Target Disease Exceptions a) Patients with extra-hepatic colorectal metastases.\n\nGeneral Inclusion Criteria:\n\n* Medical Conditions\n\n 1. Active co-infection with:\n\n 1. Both hepatitis B and C as evidenced by detectable HBV surface antigen (HBs Ag) or HBV DNA and HCV RNA, OR\n 2. Hepatitis D infection in participants with hepatitis B\n 2. Known positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).\n 3. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the participant to receive protocol therapy, or interfere with the interpretation of study results.\n 4. Participants with an active, known or suspected autoimmune disease. Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.\n 5. Participants with a condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of start of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses \\> 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.\n 6. Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.\n* Prior\u002FConcomitant Therapy\n\n 1. Participants receiving or expected to receive IFN-based therapies during the study period.\n 2. Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.\n 3. Treatment with botanical preparations (e.g., herbal supplements or traditional Chinese medicines) intended for general health support or to treat the disease under study within 2 weeks prior to start of therapy.\n* Physical and Laboratory Test Findings\n\n a. Positive pregnancy test\n* Allergies and Adverse Drug Reaction\n\n 1. History of severe hypersensitivity to a monoclonal antibody.\n 2. History of allergy or hypersensitivity to study drug components\n* Other Exclusion Criteria\n\n 1. Prisoners or participants who are involuntarily incarcerated.\n 2. Participants who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness.",{"count":485,"type":23},60,[26],"This is a single arm phase II study of adjuvant intra-dermal NA DC vaccine combined with intravenous nivolumab in patients with resectable HCC (group A) or CRLM (group B) planned for curative surgery (with\u002Fwithout local ablation).",[29,489,490,491,492],"Hepatocellular Cancer","Colorectal Cancer","Colorectal Carcinoma","Liver Metastases",[494,495,496,490,489,497,498],"Tumour neoantigens","Tumor neoantigens","Cancer vaccine","Immunotherapy","anti-PD1","2025-09-22",{"date":501,"type":42},"2025-09-23",{"date":503,"type":42},"2021-04-15",{"date":505,"type":23},"2027-06",{"name":48,"class":49},{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":12,"sex":90,"minAge":19,"maxAge":513,"enrollmentInfo":514,"targetDuration":4,"studyType":24,"phases":515,"briefSummary":516,"conditions":517,"keywords":518,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":82},"100591202","feasibility-acceptability-and-preliminary-efficacy-of-the-new-iteration-of-the-innovative-smartphone-based-care-solution-for-women-with-breast-cancer-undergoing-chemotherapy-icarebreast-a-pilot-study-research-proposal-100591202","NCT06977360","Feasibility, Acceptability and Preliminary Efficacy of the New Iteration of the Innovative Smartphone-based Care Solution for Women With Breast Cancer Undergoing Chemotherapy (iCareBreast+): A Pilot Study Research Proposal","Inclusion Criteria:\n\nWomen who:\n\n* are the age of 21 years old and above at the point of recruitment;\n* are diagnosed with stage 1-3 breast cancer;\n* will undergo chemotherapy first time (initiating or up to #4 cycles of chemo is acceptable);\n* can speak, read and write in English or Mandarin; and\n* has access to and able to use smart phone.\n\nExclusion Criteria:\n\nThose who :\n\n* are with a history of or concurrent other cancer types;\n* have been suffering from psychiatric illness (e.g., schizophrenia), anxiety disorder or other mood disorder or impaired cognitive function;\n* have alcohol or substance abuse within the previous year;\n* are undergoing concurrent psychosocial interventions; and\n* have been in the bereavement period in the last 6 months\n* are in their pregnancy.","100 Years",{"count":379,"type":23},[94],"The overall aim of the study is to evaluate the feasibility, acceptability and preliminary effects of the next iteration of iCareBreast+, an innovative breast care e-support intervention programme, by refining existing contents and building new contents based on comprehensive assessment of breast cancer women's needs and preferences among breast cancer patients undergoing chemotherapy.\n\nThe specific objectives of this study are:\n\n1. To develop a new iteration of an innovative smartphone-based self-care solution for patients with breast cancer undergoing chemotherapy (iCareBreast+);\n2. To assess the feasibility and acceptability of iCareBreast+; and\n3. To explore the preliminary effects of iCareBreast+ on the primary outcome of self-efficacy, and knowledge of breast cancer treatment, as well as secondary outcomes including anxiety, depression, health-related quality of life (HRQoL), social support and satisfaction with oncologic care.",[152],[152,519,520,521,522,523,524,525],"Digital Health","mHealth","Mobile health","Psychosocial","Randomized Controlled Trial","Self-efficacy","Chemotherapy","2025-09-11",{"date":528,"type":42},"2025-09-12",{"date":530,"type":42},"2025-05-23",{"date":532,"type":23},"2025-10-31",{"name":48,"class":49},{"id":535,"slug":536,"hasResults":12,"nctId":537,"briefTitle":538,"officialTitle":538,"acronym":539,"eligibilityCriteria":540,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":58,"enrollmentInfo":541,"targetDuration":4,"studyType":24,"phases":543,"briefSummary":544,"conditions":545,"keywords":548,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":559,"locationsCount":82},"100528443","phase-2-pembrolizumab-and-olaparib-treatment-for-relapsed-or-refractory-peripheral-t-cell-lymphoma-100528443","NCT06160843","Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma","POLAR","Inclusion Criteria:\n\n1. Male\u002Ffemale participants who are at least 21 years of age on the day of signing informed consent with histologically or cytologically-confirmed diagnosis of peripheral T-cell lymphoma (PTCL), including angioimmunoblastic T-cell lymphoma (AITL), peripheral T-cell lymphoma of T-follicular helper cell derivation (PTCL-TFH), anaplastic large cell lymphoma (ALCL), NK\u002FT-cell lymphoma (NKTCL), gamma-delta T cell lymphoma (GDTL), enteropathy associated T-cell lymphoma (EATL), monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), subcutaneous panniculitis like T-cell lymphoma, and PTCL, not otherwise specified (PTCL-NOS) will be enrolled in this study.\n2. Male participants:\n\n A male participant must agree to use a contraception as detailed in Appendix 3 of this protocol during the treatment period and for at least the time needed to eliminate the study intervention (180 days for Olaparib; no requirement for pembrolizumab) after the last dose of study treatment and refrain from donating sperm during this period.\n3. A female participant is eligible to participate if she is not pregnant (see Appendix 3), not breastfeeding, and at least one of the following conditions applies: a. Not a woman of childbearing potential (WOCBP) as defined in Appendix 3 OR b. A WOCBP who agrees to follow the contraceptive guidance in Appendix 3 during the treatment period and for at least the time needed to eliminate the study intervention (180 days for Olaparib; 120 days for pembrolizumab) after the last dose of study treatment.\n4. Participants must have progressed on treatment with at least one prior systemic anti-cancer therapy including investigational agents. These may include an anti-PD-1\u002FL1 mAb administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies. PD-1 treatment progression is defined by meeting all of the following criteria:\n\n 1. Has received at least 2 doses of an approved anti-PD-1\u002FL1 mAb.\n 2. Has demonstrated disease progression after anti-PD-1\u002FL1 as defined by Cheson response criteria. The initial evidence of PD is to be confirmed by a second assessment no less than 4 weeks from the date of the first documented disease progression, in the absence of rapid clinical progression (as defined in 4.c).\n 3. Progressive disease has been documented within 12 weeks from the last dose of anti-PD-1\u002FL1 mAb.\n\n * Progressive disease is determined according to Cheson response criteria.\n * This determination is made by the investigator. Once disease progression is confirmed, the initial date of disease progression documentation will be considered the date of disease progression.\n\n Progression on other systemic anti-cancer therapy including investigational agents is defined by radiographic disease progression based on Cheson response criteria.\n5. The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.\n6. Have measurable disease based on Cheson criteria. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.\n7. Archival tumor tissue sample or newly obtained \\[core, incisional or excisional\\] biopsy of a tumor lesion not previously irradiated has been provided. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue.\n8. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 7 days prior to the first dose of study intervention.\n9. Have adequate organ function as defined in the following. Specimens must be collected within 10 days prior to the start of study intervention.\n\n * Absolute neutrophil count (ANC)≥500\u002FμL\n * Platelets ≥25 000\u002FμL\n * Hemoglobin ≥8 g\u002FdL\n * Creatinine OR Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≤1.5 × ULN OR ≥30 mL\u002Fmin for participant with creatinine levels \\>1.5 × institutional ULN\n * Total bilirubin ≤1.5 ×ULN OR direct bilirubin ≤ULN for participants with total bilirubin levels \\>1.5 × ULN\n * AST (SGOT) and ALT (SGPT) ≤2.5 × ULN (≤5 × ULN for participants with liver metastases)\n * International normalized ratio (INR) OR prothrombin time (PT) ≤1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants\n * Activated partial thromboplastin time (aPTT) ≤1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants\n10. Hepatitis B and C screening tests are required:\n\n * Hepatitis B positive subjects\n\n * Participants who are HBsAg positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to enrolment.\n * Participants should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post completion of study intervention.\n * Participants with history of HCV infection are eligible if HCV viral load is undetectable at screening.\n\n * Participants must have completed curative anti-viral therapy at least 4 weeks prior to enrolment.\n11. Participant has a life expectancy of at least 3 months\n\nExclusion Criteria:\n\n1. A WOCBP who has a positive urine pregnancy test within 72 hours prior to treatment (see Appendix 3). If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n2. Has received prior systemic investigational agents within 4 weeks (or shorter interval for kinase inhibitors or other short half-life drugs, per investigator discretion) or has used an investigational device within 4 weeks prior to treatment.\n3. Has received prior radiotherapy within 2 weeks of start of study intervention or radiation-related toxicities requiring corticosteroids. Note: Two weeks or fewer of palliative radiotherapy for non-CNS disease, with a 1-week washout, is permitted.\n4. Has received a live vaccine or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.\n5. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.\n6. Known additional malignancy that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of the bladder that have undergone potentially curative therapy are not excluded.\n7. Has known active CNS metastases and\u002For carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study intervention.\n8. Has severe hypersensitivity (≥Grade 3) to pembrolizumab and\u002For any of its excipients.\n9. Has active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid)\n10. Has a history of (non-infectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease.\n11. Has an active infection requiring systemic therapy.\n12. Has a known history of Human Immunodeficiency Virus (HIV) infection.\n13. Concurrent active Hepatitis B (defined as HBsAg positive and\u002For detectable HBV DNA) and Hepatitis C virus (defined as anti-HCV Ab positive and detectable HCV RNA) infection.\n\n Note: HIV, Hepatitis B and C screening tests are required.\n14. Has not adequately recovered from major surgery or has ongoing surgical complications.\n15. Has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n16. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n17. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 180 days after the last dose of trial treatment.\n18. Has had an allogenic tissue\u002Fsolid organ transplant.",{"count":542,"type":23},24,[26],"The goal of this clinical trial is to evaluate the efficacy and safety of Pembrolizumab in combination with Olaparib in participants with relapsed\u002Frefractory Peripheral T-cell Lymphoma (PTCL).\n\nThe study mainly aims to evaluate:\n\n* objective response rate (ORR) as per Cheson response criteria assessed by the independent central review\n* overall survival and progression-free survival\n* adverse events by CTCAE version 5.0\n\nThe administration of Pembrolizumab and Olaparib to participants will occur on Day 1 of each 3-week dosing cycle and will continue until disease progression or unacceptable toxicity, up to 35 cycles. Treatment with Olaparib will proceed continuously from Day 1 of Cycle 1, in 3-week dosing cycles in parallel with Pembrolizumab, up to 35 cycles, unless specific withdrawal\u002Fdiscontinuation criteria are met. After the end of treatment, each subject will be followed for 30 days for adverse event (AE) monitoring (serious AEs \\[SAEs\\] will be collected for 90 days after the end of treatment or 30 days after the end of treatment if the subject initiates new anticancer therapy, whichever is earlier).",[546,547],"Relapsed Peripheral T-Cell Lymphoma","Refractory Peripheral T-Cell Lymphoma",[549,550,551],"Pembrolizumab","Olaparib","Peripheral T-Cell Lymphoma","2025-09-04",{"date":554,"type":42},"2025-09-05",{"date":556,"type":42},"2024-07-01",{"date":558,"type":23},"2028-01",{"name":48,"class":49},{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":566,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":90,"minAge":19,"maxAge":58,"enrollmentInfo":568,"targetDuration":4,"studyType":24,"phases":570,"briefSummary":571,"conditions":572,"keywords":575,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":585,"locationsCount":418},"100512793","breast-cancer-exercise-intervention-study-100512793","NCT05957068","Breast Cancer Exercise Intervention Study","Breast Cancer Exercise Intervention Study (BREXINT)","BREXINT","Inclusion Criteria:\n\n* Patients with histologically or cytologically proven stage 1, 2, or 3 breast cancer\n* Patients who have undergone curative breast surgery\n* Patients who have received (neo)adjuvant chemotherapy (if given) and\u002For radiotherapy (if given)\n* Females aged 21 years and older\n* ≤ 8 weeks from breast surgery, or the last adjuvant chemotherapy or radiotherapy session, whichever is latest.\n\nExclusion Criteria:\n\n* Cardiovascular, respiratory, musculoskeletal problems that preclude moderate physical activity.\n* Major medical problems that are deemed by the investigator to be unsuitable for enrollment.",{"count":569,"type":23},2156,[94],"This is a 24-week exercise programme consisting of aerobic exercise and muscle strength training, 3 sessions per week. The first 9 sessions are supervised by physiotherapists in person, followed by 63 sessions monitored remotely (video) or supervised by trainers at ActiveSG (Sport Singapore) gyms.",[573,574],"Early-stage Breast Cancer","Locally Advanced Breast Cancer",[566,576,577,578],"Muscular Strength","Cardiorespiratory Fitness","Quality of Life","2025-09-03",{"date":554,"type":42},{"date":582,"type":42},"2023-07-01",{"date":584,"type":23},"2033-05-31",{"name":48,"class":49},{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":591,"acronym":4,"eligibilityCriteria":592,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":58,"enrollmentInfo":593,"targetDuration":4,"studyType":194,"phases":4,"briefSummary":594,"conditions":595,"keywords":598,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":610,"locationsCount":82},"100438243","using-qpop-to-predict-treatment-for-sarcomas-and-melanomas-100438243","NCT04986748","Using QPOP to Predict Treatment for Sarcomas and Melanomas","Q-SAM (Using QPOP to Predict Treatment for Sarcomas and Melanomas)","Inclusion Criteria:\n\n* Diagnosis of sarcoma or melanoma\n* At least 1 tumour lesion amenable to fresh biopsy or resection\n* Signed informed consent from patient or legal representative\n* Able to comply with study-related procedures\n\nExclusion Criteria:\n\n* There are no specific exclusion criteria if patients meet the inclusion criteria",{"count":92,"type":23},"This is a multi-cohort proof of concept study involving patients with sarcomas or melanomas. Patient models, both two- and three-dimensional, will be derived from tumour samples. These will then be used to evaluate drug sensitivities ex vivo.\n\nEnrolled patients will undergo resections or biopsies as part of standard-of-care, which will be used to generate patient models. Patients will receive standard-of-care systemic treatment. Patient models will also be subjected up to a 14-drug screening panel. The majority of drugs in the respective drug panels has been shown to have activity in the respective cancers and would be used in the standard-of-care setting by treating physicians.",[596,597],"Sarcoma","Melanoma",[599,600,601,602,603],"Tumour-derived models","Organoids","Ex vivo drug testing","Personalised therapy","QPOP","2025-06-29",{"date":606,"type":42},"2025-07-01",{"date":608,"type":42},"2020-09-08",{"date":392,"type":23},{"name":48,"class":49},{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":4,"eligibilityCriteria":617,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":58,"enrollmentInfo":618,"targetDuration":4,"studyType":194,"phases":4,"briefSummary":620,"conditions":621,"keywords":623,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":418},"100548239","a-pan-asian-clinical-database-of-egfr-exon-20-insertion-mutated-nsclc-100548239","NCT06418412","A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC","A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated Non-small Cell Lung Cancer (NSCLC)","Inclusion Criteria:\n\n1. Histologically confirmed advanced NSCLC\n2. Positive testing result from any locally approved test (including but not limited to RT-PCR, Cobas and NGS) for EGFR exon 20 insertion mutation\n3. Diagnosis date from 1 Jan 2013 to 31 Dec 2024 (to allow for minimum 12 months of follow-up clinical and treatment outcome data)\n4. Male or female adults, age as defined by local regulations\n\nExclusion Criteria:\n\n1\\. Patients without an EGFR exon 20 insertion mutation",{"count":619,"type":23},600,"There are limited in depth studies on the epidemiology and clinical management of EGFR exon 20 insertion mutated NSCLC in Asia. In addition, there is preliminary data suggesting the exact location of the insertion and variant may influence the response and efficacy to novel EGFR targeted therapies.\n\nThis study aims to fill this knowledge gap, by comprehensively characterising the epidemiology and clinical outcomes of Asian advanced EGFR exon 20 insertion mutated NSCLC patients.",[622],"Advanced EGFR Exon 20 Insertion Mutated Non-Small Cell Lung Cancer",[624,625],"EGFR EXON20 insertion","NSCLC (Non small cell lung cancer)","2025-06-11",{"date":628,"type":42},"2025-06-12",{"date":630,"type":42},"2024-03-15",{"date":632,"type":23},"2026-12-31",{"name":48,"class":49},{"id":635,"slug":636,"hasResults":12,"nctId":637,"briefTitle":638,"officialTitle":638,"acronym":4,"eligibilityCriteria":639,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":58,"enrollmentInfo":640,"targetDuration":4,"studyType":194,"phases":4,"briefSummary":642,"conditions":643,"keywords":647,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":652,"lastUpdatePostDateStruct":653,"startDateStruct":654,"completionDateStruct":656,"leadSponsor":657,"locationsCount":82},"100388605","discovery-of-biomarkers-for-intrinsic-radiation-sensitivity-in-cancer-patients-100388605","NCT04340024","Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients","Inclusion Criteria:\n\n* Patients with severe side effects from radiotherapy\n* Patients with a type of cancer that is associated with sensitivity to radiotherapy\n\nExclusion Criteria:\n\n* Age of patient must be between 21 (inclusive) and 99 (exclusive)",{"count":641,"type":23},5000,"Patients with cancers that are sensitive to radiotherapy treatment and\u002For patients who have experienced severe acute\u002F late side effects to radiotherapy will be recruited to the study. Blood and\u002For matched tumour-normal tissue pairs will be collected. Blood and\u002For tissue samples will be processed and studied for genetic and biochemical markers that have potential to be used for predicting sensitivity to radiation.",[644,645,646],"Nasopharyngeal Cancer","Prostate Cancer","Other Cancer",[648,34,649,650,651],"Radiotherapy","Genomics","Immunomics","Precision medicine","2025-06-10",{"date":626,"type":42},{"date":655,"type":42},"2015-09-30",{"date":632,"type":23},{"name":48,"class":49},{"id":659,"slug":660,"hasResults":12,"nctId":661,"briefTitle":662,"officialTitle":662,"acronym":663,"eligibilityCriteria":664,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":58,"enrollmentInfo":665,"targetDuration":4,"studyType":24,"phases":667,"briefSummary":668,"conditions":669,"keywords":671,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":677,"lastUpdatePostDateStruct":678,"startDateStruct":680,"completionDateStruct":682,"leadSponsor":684,"locationsCount":110},"100534909","timely-interventions-to-enable-and-reach-patients-with-heart-failure-and-their-caregivers-with-palliative-care-100534909","NCT06244953","Timely Interventions to Enable and Reach Patients With Heart Failure, and Their Caregivers With Palliative Care","TIER-HF-PC","Inclusion Criteria:\n\n* Patients:\n\n 1. 21 years or older and\n 2. able to communicate in English or Chinese and\n 3. be of stage C or D heart failure, as defined by American College of Cardiology\u002FAmerican Heart Association (ACC\u002FAHA) classification system and\n 4. have functional limitation of New York Heart Association (NYHA) functional status of at least 2 or more and\n 5. be deemed by their cardiologist's clinical judgement to have an expected prognosis of at least 6 months survival, and\n 6. have had a heart failure related hospitalization event (e.g. symptomatic decompensated heart failure) within 6 months prior to recruitment and\n 7. have a phone that allows telecommunication.\n* Caregivers must meet all the following inclusion criteria to be eligible for the study :\n\n * direct, unpaid, family caregiver of the patient;\n * self-reported by the patient to be the main person to be either:\n * responsible for up to 4 hours a day of caregiving tasks\n * and\u002For decision maker\u002Fspokesperson with the medical team\n * Caregiver may or may not live in the same residence as the patient.\n * Caregivers must be 21 years and above.\n * Able to communicate in English or Chinese.\n\nExclusion Criteria:\n\n* Patients:\n\n 1. have cognitive impairment (e.g., dementia)\n 2. have severe, untreated, active mental illness (e.g., major depressive disorder)\n 3. have ventricular assist device implant.\n 4. have non-reversible hearing or visual loss or\n 5. are active drug abuser or\n 6. already known to a palliative care service.\n* Caregivers who meet any of the exclusion criteria at baseline will be ineligible for the study:\n\n * have cognitive impairment (e.g., dementia) or\n * have severe, untreated, active mental illness (e.g., major depressive disorder)\n * have non-reversible hearing or visual loss.\n * are active drug abuser or\n * are a domestic helper for the patient",{"count":666,"type":23},240,[94],"There is evidence for the effectiveness and feasibility of the individual components of TIER-HF-PC, however there is a need to test how these individual components interact to allow the researchers to deliver TIER-HF-PC as a model of care in its totality. In the short term, this study will assess if TIER-HF-PC is beneficial for patients and caregivers.",[670],"Heart Failure",[672,673,674,675,676,663],"Palliative care","Patients","Caregivers","Distress thermometer (DT)","Integrated Palliative Care Outcome Scale (IPOS)","2025-04-06",{"date":679,"type":42},"2025-04-08",{"date":681,"type":42},"2024-08-14",{"date":683,"type":23},"2027-10-31",{"name":48,"class":49},""]